HbA1c

There are 3,961 papers on HbA1c in aging research: 915 trials and 2,164 observational studies in people, 42 in animals, 2 in cells, 662 reviews.

Biomarker

3,961 papers study it511 more mention it1,934 findings

427 new papers in 30 daysSee all 4,472 papers on HbA1c

At a glance

A human cohort links HbA1c with mortality in a U-shaped pattern in the general population, while an observational preprint links higher HbA1c with greater frailty in adults with diabetes. Human trials report HbA1c reductions with semaglutide and resistance training; a dapagliflozin trial shows no clear effect.

1,934 findings in 1,603 papers from 1978 to 2026, 436 of them since April 2026

“Higher baseline HbA1c was associated with lower remission rates (HR 0.23, 95% CI 0.18-0.29, p < 0.001)”
Impact of Metformin Plus Lifestyle Intervention Compared With Lifestyle Intervention Alone on Prediabetes Remission in Participants With Impaired Glucose Regulation: The China DPP StudyDiabetes, obesity & metabolism2026doi:10.1111/dom.71271
  • Human trial915
  • Humans2,164
  • Animals42
  • Cells2
  • In silico50

Interventions

218

Tirzepatide

downin humans35−1.5% to −0.6%

35 studies
  1. Tirzepatide decreases HbA1c in humans (unadjusted indirect comparison with semaglutide) (-0.10% vs semaglutide [-0.15, -0.05]).

    “HbA1c(-0.08% [-0.13,-0.03], -0.10% [-0.15, -0.05])”

    Human trialunadjusted indirect comparison with semaglutide15 mg/week

    Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes

    International journal of obesity (2005)

  2. Tirzepatide decreases HbA1c in adults with early uncontrolled T2D.

    “tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y”

    Human trialin adults with early uncontrolled T2D2 y

    In adults with early uncontrolled T2D, tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y

    Annals of internal medicine

  3. Tirzepatide decreases HbA1c in a patient with severe hypertriglyceridemia and type 2 diabetes (to 5.5% from 7.0%).

    “HbA1c improved to 5.5%”

    Human trialin a patient with severe hypertriglyceridemia and type 2 diabetesfemalesn = 1

    Tirzepatide in recurrent hypertriglyceridemia-mediated pancreatitis and type 2 diabetes: a case report

    Cardiovascular diabetology. Endocrinology reports

  4. Tirzepatide decreases HbA1c in humans (compared with dulaglutide) (-2.18% (TZP) vs -1.28% (dula) at six months).

    “At six months HbA1c was reduced more with TZP than on dula (-2.18%, -1.28%, p<0.001)”

    Human trialcompared with dulaglutideup to 15 mg/weeksix monthsn = 449

    The SURPASS-CVOT Retinopathy Substudy: Retinal Status after Treatment with Tirzepatide or Dulaglutide in Patients with Type 2 Diabetes and Risk for Progressive Retinopathy

    ADA Scientific Sessions 2026 abstract

  5. Tirzepatide decreases HbA1c in humans (switch from dulaglutide, across prespecified baseline subgroups).

    “Reductions in HbA1c and body weight at week 40 were significant and consistently greater with tirzepatide across all prespecified baseline subgroups.”

    Human trialswitch from dulaglutide, across prespecified baseline subgroupsweek 40

    Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH

    BMJ open diabetes research & care

  6. Tirzepatide decreases HbA1c in humans (-0.77% (95% CI −0.98 to −0.56)).

    “At week 40, the estimated treatment difference of tirzepatide compared with dulaglutide was −0.77% (95% CI −0.98 to −0.56, p<0.001) for HbA1c and −6.9 kg (95% CI−8.3 to −5.5, p<0.001) for body weight.”

    Human trial40-week treatment periodn = 282

    Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH

    BMJ open diabetes research & care

  7. Tirzepatide decreases HbA1c in humans (tirzepatide 15 mg versus semaglutide 2.4 mg at maximum doses) (MD 0.33%; 95% CI 0.20, 0.46).

    “tirzepatide was also more effective than semaglutide in reducing HbA1c (MD 0.33%; 95% CI: 0.20, 0.46)”

    Human trialtirzepatide 15 mg versus semaglutide 2.4 mg at maximum doses15 mg versus 2.4 mg

    Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide

    Journal of diabetes

  8. Tirzepatide is linked with lower HbA1c in humans (-1.5%).

    “HbA1c levels and BMI decreased over 24 weeks after initiation of low-dose tirzepatide (HbA1c, -1.5%; BMI, -1.5 kg/m 2 ; both p < 0.001).”

    Humansaverage 4.5 ± 1.0 mg/week24 weeksn = 88

    Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study

    Endocrine journal

  9. Tirzepatide is linked with lower HbA1c in humans (combined with a standardized low-carbohydrate diet and tailored physical activity) (5.5 ± 0.4% to 5.2 ± 0.1%).

    “Metabolic parameters were also improved, including HbA1c (from 5.5 ± 0.4% to 5.2 ± 0.1%, p = 0.007)”

    Humanscombined with a standardized low-carbohydrate diet and tailored physical activityinitiated at 2.5 mg once weekly, increased to 5 mg; mean 5.32 mg24 weeksn = 122

    Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity

    Journal of diabetes and its complications

  10. Tirzepatide is linked with lower HbA1c in humans (decreased by 16.0%).

    “Fasting glucose, HbA1c, triglycerides, and alanine aminotransferase decreased by 19.5%, 16.0%, 8.5%, and 10.6%, respectively”

    Humans12 months

    Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study

    Journal of the Endocrine Society

All 36

More on Tirzepatide

Semaglutide

downin humans28no changein humans1downin rats1−1.1% to −0.5%

30 studies
  1. Semaglutide decreases HbA1c in humans (A1c 8.0% to 6.6%).

    “improved diabetes control (A1c 8.0% to 6.6%)”

    Human trialFamilial hypobetalipoproteinemia and type 2 diabetes mellitus; concurrent fat-soluble vitamin supplementation and alendronate1 mg weekly18 monthsmalesn = 1

    A Favorable Response to Semaglutide in Advanced Hepatic Fibrosis Secondary to Familial Hypobetalipoproteinemia

    AHA Scientific Sessions 2026 abstract

  2. Semaglutide decreases HbA1c in humans (-21.1 mmol/mol).

    “significant reductions in HbA1c (-21.1 mmol/mol, P < .0001)”

    Human trial≤2.0 mg weekly6 months

    Potential bone marrow-driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes

    European heart journal

  3. Semaglutide decreases HbA1c in humans (−21.1 mmol/mol).

    “After 6 months of semaglutide, significant reductions in HbA1c (−21.1 mmol/mol, P <.0001), weight (−6.7 kg, P <.001), BMI (−2.5 kg/m, P <.001), and hsCRP (−1.0 mg/L, P =.005) were observed.”

    Human trial24 weeksn = 16

    Potential bone marrow-driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes

    European heart journal

  4. Semaglutide decreases HbA1c in humans (− 0.64%-points (95% CI − 0.71, − 0.56)).

    “Mean change in HbA1c (95% confidence interval [CI]) from baseline to month 6 was − 0.64%-points (− 0.71, − 0.56) (p < 0.0001) for the overall combined semaglutide–SGLT2i group.”

    Human trial6 monthsn = 1,855

    Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis

    Diabetes therapy : research, treatment and education of diabetes and related disorders

  5. Semaglutide decreases HbA1c in humans.

    “HbA1c levels were reduced through week 24 from baseline in the test vs. reference group.”

    Human trial24 weeksn = 217

    Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: A phase 3, randomized, active-controlled, multicenter, non-inferiority trial (WIN-IND study)

    Metabolism open

  6. Semaglutide decreases HbA1c in humans (Added to standard treatment for inadequately controlled type 2 diabetes mellitus) (HbA1c decreased from 8.6±0.7% to 7±1%; difference: -1.6 percentage points).

    “At 24 weeks, a reduction in glycosylated hemoglobin (HbA1c: 8.6±0.7% to 7±1%, difference: -1.6%)”

    Human trialAdded to standard treatment for inadequately controlled type 2 diabetes mellitus0.5 or 1 mg weekly24 weeks79.8% womensn = 104

    Effectiveness of Weekly Semaglutide Treatment (0.5 or 1 mg) in Chilean Patients with Type 2 Diabetes Mellitus

    Revista medica de Chile

  7. Semaglutide decreases HbA1c in humans (−0.9 percentage points).

    “For the primary endpoint, a reduction in HbA1c from 7.9% (63 mmol/mol) to 6.9% (52 mmol/mol) was observed from BL to EOS, with an estimated mean change of −0.9 (95% CI: −1.2; −0.6) percentage points (p < 0.0001) or −9.9 (95% CI: −13.1; −6.6) mmol/mol (Figure 1, Supplementary table S5).”

    Human trial34-44 weeksn = 97

    Real-world use of oral semaglutide in adults with type 2 diabetes

    Danish medical journal

  8. Semaglutide decreases HbA1c in humans (persistent on dose to week 52, compared with 14 mg) (-2.1% vs -1.6% change from baseline).

    “Individuals persistent on 25mg OS experienced a greater HbA1c reduction of -2.1% (baseline HbA1c 9.0%) compared to -1.6% (baseline HbA1c 8.9%) for those on 14mg.”

    Human trialpersistent on dose to week 52, compared with 14 mg25 mg52 weeksn = 272

    HbA1c and Weight Outcomes for Individuals with T2D Persistent on 25mg Oral Semaglutide: A PIONEER PLUS Post-Hoc Analysis

    ADA Scientific Sessions 2026 abstract

  9. Semaglutide decreases HbA1c in humans (adjunct to standard-of-care insulin vs SOC, Period 1 (weeks 1 to 26)) (-0.45% HbA1c vs SOC).

    “In Period 1, HbA1c was reduced by 0.45% (95% CI -0.78, -0.127; p=0.0072)”

    Human trialadjunct to standard-of-care insulin vs SOC, Period 1 (weeks 1 to 26)weekly injectionuptitrated to 1.0 mg weekly26 weeksn = 78

    Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide, and Dapagliflozin (TTT1): A Phase 3 Clinical Trial

    ADA Scientific Sessions 2026 abstract

  10. Semaglutide decreases HbA1c in humans across baseline glycemia subgroups (nondiabetes, prediabetes, type 2 diabetes).

    “HbA1c, BP, triglycerides, non-HDL, and hsCRP improved”

    Human trialacross baseline glycemia subgroups (nondiabetes, prediabetes, type 2 diabetes)2.4 mgup to week 72n = 800

    Longitudinal Dynamics of Cardiometabolic Parameters in a MASH Population Stratified by Baseline Glycemia and Treated with Semaglutide: Post Hoc Insights from the ESSENCE Trial Part 1

    ADA Scientific Sessions 2026 abstract

All 33

More on Semaglutide

GLP-1 receptor agonists

downin humans25no changein humans1upin humans1downin reviews1−0.6% to −0.3%

28 studies
  1. GLP-1 receptor agonists decrease HbA1c in humans (add-on to background glucose-lowering therapy) (MD -0.48% (95% CI -0.83 to -0.14)).

    “low certainty indicated an HbA1c reduction (MD, - 0.48%; 95% CI, - 0.83 to - 0.14)”

    Human trialadd-on to background glucose-lowering therapy

    Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis

    Frontiers in endocrinology

  2. GLP-1 receptor agonists decrease HbA1c in diabetic patients with inflammatory bowel disease (7.11% (95% CI 6.62 to 7.59) to 6.76% (95% CI 6.35 to 7.16)).

    “HbA1c, in diabetics, from 7.11% (95% CI: 6.62 to 7.59) to 6.76% (95% CI: 6.35 to 7.16)”

    Human trialin diabetic patients with inflammatory bowel disease

    Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis

    Digestive diseases (Basel, Switzerland)

  3. GLP-1 receptor agonists decrease HbA1c in kidney-transplanted people with post-transplant diabetes mellitus (−0.6% at 6 months (95% CI −0.8 to −0.4); −0.7% at 12 and 18 months).

    “HbA1c significantly decreased by −0.6% at 6 months (95% CI −0.8 to −0.4)”

    Human trialin kidney-transplanted people with post-transplant diabetes mellitus6 monthsn = 42

    GLP-1 Receptor Agonists (GLP-1RAs) in Kidney-Transplanted (KTX) People with Diabetes: Ad Interim Results of an 18-Month Trial

    ADA Scientific Sessions 2026 abstract

  4. GLP-1 receptor agonists decrease HbA1c in type 2 diabetes, versus placebo (MD -1.4% [-1.6%, -1.2%] for tirzepatide 15 mg).

    “All once-weekly GLP-1RAs outperformed placebo in reducing HbA1c”

    Human trialin type 2 diabetes, versus placebo

    Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis

    Diabetes research and clinical practice

  5. GLP-1 receptor agonists are linked with lower HbA1c in humans (versus SGLT2 inhibitor initiators) (-0.261%).

    “HbA1c decreased more with GLP-1RA (-0.261%; P = .032)”

    Humansversus SGLT2 inhibitor initiators12 months

    Comparative Weight-Loss Outcomes Following Initiation of GLP-1 Receptor Agonists versus SGLT2 Inhibitors: A Real-World Active Comparator Study

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

  6. GLP-1 receptor agonists are linked with lower HbA1c in humans (switching among discontinuers of oral semaglutide) (Δ = -0.98%).

    “switching to another GLP1 receptor agonist was the most common strategy (36.2%) and resulted in a further HbA1c reduction (Δ = -0.98%; p = 0.005)”

    Humansswitching among discontinuers of oral semaglutiden = 232

    Oral Semaglutide in Routine Clinical Practice: 24-Month Real-World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes

    Diabetes, obesity & metabolism

  7. GLP-1 receptor agonists are linked with lower HbA1c in humans (-0.71% HbA1c reduction).

    “GLP-1 RA users achieved a mean adjusted weight loss of -5.73% (p = 0.001) and an HbA1c reduction of -0.71% (p = 0.018)”

    Humans12 monthsn = 610

    Safety and Efficacy of GLP-1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes

    Annals of clinical and translational neurology

  8. GLP-1 receptor agonists are linked with lower HbA1c in humans (alone or as dual GIP/GLP-1RA therapy, in people with obesity and type 1 diabetes) (-0.48% (95% CI -0.74 to -0.22)).

    “HbA1c (-0.48%; 95% CI: -0.74, -0.22; p < 0.001)”

    Humansalone or as dual GIP/GLP-1RA therapy, in people with obesity and type 1 diabetes12 monthsn = 70

    Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide

    Diabetes/metabolism research and reviews

  9. GLP-1 receptor agonists are linked with lower HbA1c in good responders with type 2 diabetes (-2.9 percentage points).

    “HbA1c levels fell from 9.2% to 6.3% in good responders and 8.4% to 8.1% in poor responders, resulting in an absolute HbA1c reduction of 2.9% and 0.3%, respectively.”

    Humansin good responders with type 2 diabetesafter 3 monthsn = 3,194

    GLP1R Variants and Polygenic Risk Underlie Heterogeneous Response to GLP-1 Receptor Agonists in Type 2 Diabetes

    medRxivPreprint

  10. GLP-1 receptor agonists were not clearly linked with HbA1c in Wolfram syndrome participants also on insulin.

    “No statistically significant changes in HbA1c or body mass index were observed at one or two years.”

    Humansin Wolfram syndrome participants also on insulinone or two years

    Evaluating the use of GLP-1 receptor agonists in Wolfram syndrome patients

    Frontiers in endocrinology

All 28

More on GLP-1 receptor agonists

SGLT2 inhibitors

downin humans11no changein humans4−0.4%

15 studies
  1. SGLT2 inhibitors decrease HbA1c in humans (type 2 diabetes; single-arm study) (−0.90 percentage points (9.8 mmol/mol); 95% CI −1.10 to −0.69; P<0.001).

    “Over 12 weeks, HbA1c decreased by 0.90 percentage points (9.8 mmol/mol; 95% CI, −1.10 to −0.69)”

    Human trialtype 2 diabetes; single-arm study12 weeksn = 44

    Glycemia, Dietary Intake, and Food Craving During SGLT2 Inhibitor Treatment in Type 2 Diabetes: A Single-Arm Interventional Study

    Frontiers in endocrinology

  2. SGLT2 inhibitors showed no clear effect on HbA1c in humans (add-on to background glucose-lowering therapy) (MD -0.09% (95% CI -0.27 to 0.08)).

    “little or no clinically important further benefit observed for HbA1c”

    Human trialadd-on to background glucose-lowering therapy

    Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis

    Frontiers in endocrinology

  3. SGLT2 inhibitors decrease HbA1c in humans (as add-on to insulin therapy) (MD -0.29%).

    “Reductions were observed in HbA1c (MD -0.29%; p = 0.07)”

    Human trialas add-on to insulin therapy

    Beyond insulin therapy: Comparing relative benefits of adding SGLT2 versus DPP4 inhibitors in poorly controlled type 2 diabetic patients: A systematic review and meta-analysis

    Primary care diabetes

  4. SGLT2 inhibitors are linked with lower HbA1c in humans (type 2 diabetes without comorbidities).

    “Significant reductions were observed in glucose and HbA1c levels.”

    Humanstype 2 diabetes without comorbidities6 monthsn = 206

    The effect of SGLT2 inhibitors on volume-related laboratory and metabolic parameters in older adults: a 6-month retrospective study

    Intercontinental Journal of Internal Medicine

  5. SGLT2 inhibitors were not clearly linked with HbA1c in humans (Kidney transplant recipients with post-transplantation diabetes mellitus) (52 vs. 49 mmol/mol; p = .11).

    “Our study could not demonstrate improved metabolic parameters in PTDM patients treated with SGLT2-inhibitors at 5 years post transplantation.”

    HumansKidney transplant recipients with post-transplantation diabetes mellitus5 years after transplantationn = 232

    Sodium-Glucose Cotransporter-2 Inhibitor Use in Kidney Transplant Recipients With Post-Transplantation Diabetes Mellitus - A Cross-Sectional Study

    Transplantation proceedings

  6. SGLT2 inhibitors are linked with lower HbA1c in humans (real-life retrospective cohort; short-term follow-up) (median 7.8% to 7.3% short-term).

    “HbA1c from 7.8 [7.1-8.8] to 7.3 [6.7-7.7] and 7.3% [6.9-8] (p < 0.01 and p = 0.05, respectively)”

    Humansreal-life retrospective cohort; short-term follow-up6-18 months

    Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real-Life Experience From a National Reference Network

    Diabetes, obesity & metabolism

  7. SGLT2 inhibitors were not clearly linked with HbA1c in humans after multivariable adjustment.

    “Descriptive between-group differences in HbA1c were observed at 6 and 12 months, but were not confirmed after multivariable adjustment.”

    Humansafter multivariable adjustment6 and 12 months

    SGLT2 inhibitors in kidney transplant recipients: metabolic changes, potassium-related safety and implications for albuminuria assessment

    Frontiers in transplantation

  8. SGLT2 inhibitors are linked with lower HbA1c in humans (patients with baseline HbA1c ≥8%) (9.6% ± 1.3% to 7.6% ± 0.7%).

    “HbA1c remained stable overall but decreased significantly in patients with baseline HbA1c ≥ 8% (9.6% ± 1.3% to 7.6% ± 0.7%; p = 0.001)”

    Humanspatients with baseline HbA1c ≥8%

    Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real-World National Study

    Diabetes, obesity & metabolism

  9. SGLT2 inhibitors are linked with lower HbA1c in humans (all initiators with available follow-up data) (-0.62% (SD 1.53, n=105); -0.79% in diabetes/metabolic subgroup (SD 1.75; n=76)).

    “HbA1c decreased by 0.62% among all initiators with available follow up data (SD 1.53, n=105), and by 0.79% in the diabetes/metabolic subgroup (SD 1.75; n=76).”

    Humansall initiators with available follow-up datan = 105

    Real-World Safety and Clinical Outcomes of SGLT2 Inhibitors in 195 Pediatric Patients

    ADA Scientific Sessions 2026 abstract

  10. SGLT2 inhibitors are linked with lower HbA1c in humans (Type 2 Diabetes) (control: -0.093% vs. treatment: -0.76%).

    “HbA1c (control: -0.093% vs. treatment: -0.76%; p ≤ 0.001)”

    HumansType 2 Diabetes> 6 monthsn = 200

    Impact of SGLT2 Inhibitors on Multiple Cardiometabolic Risk Factors: A Retrospective Cohort Study

    Journal of clinical medicine

All 15

More on SGLT2 inhibitors

Orforglipron

downin humans11upin humans1

12 studies
  1. Orforglipron decreases HbA1c in humans (Type 2 diabetes inadequately controlled with metformin; compared with dapagliflozin).

    “In T2D inadequately controlled with metformin, orforglipron reduced HbA1c more than dapagliflozin at 40 wk”

    Human trialType 2 diabetes inadequately controlled with metformin; compared with dapagliflozin40 weeks

    In T2D inadequately controlled with metformin, orforglipron reduced HbA1c more than dapagliflozin at 40 wk

    Annals of internal medicine

  2. Orforglipron decreases HbA1c in humans (head-to-head comparison, 36 mg vs 12 mg maintenance dose).

    “greater reductions in percentage body weight change (p < 0.00001), absolute body weight change (p < 0.00001), body mass index (p < 0.00001), HbA1c”

    Human trialhead-to-head comparison, 36 mg vs 12 mg maintenance dose36 mg versus 12 mgn = 3,459

    Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis

    BMC endocrine disorders

  3. Orforglipron decreases HbA1c in humans (MD: 0.08% points; CI: 0.05 to 0.10).

    “The 36-mg dose of Orforglipron was associated with a significantly greater reduction in HbA1c (in percentage points) compared with the 12-mg dose (MD: 0.08% points; CI: 0.05 to 0.10; p < 0.00001; I2 = 39%).”

    Human trial26 to 72 weeksn = 3,459

    Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis

    BMC endocrine disorders

  4. Orforglipron decreases HbA1c in humans.

    “Once-daily orforglipron treatment in older adults ≥65 years of age with overweight or obesity with or without T2D was associated with significantly reduced body weight and HbA1c levels at Week 72 compared with placebo”

    Human trial72 weeksn = 616

    Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials

    Obesity pillars

  5. Orforglipron decreases HbA1c in humans (versus dapagliflozin in type 2 diabetes inadequately controlled with metformin).

    “At week 40, all OFG doses were superior to DAPA in reducing HbA1c”

    Human trialversus dapagliflozin in type 2 diabetes inadequately controlled with metformin3, 12, 36 mg once daily40 weeksn = 962

    Orforglipron vs. Dapagliflozin in Type 2 Diabetes Inadequately Controlled with Metformin

    ADA Scientific Sessions 2026 abstract

  6. Orforglipron decreases HbA1c in humans (add-on to titrated insulin glargine) (1.54 to 2.05% vs 0.77% with placebo).

    “Mean HbA1c decreased by 1.54 to 2.05% in the OFG groups vs 0.77% with PBO.”

    Human trialadd-on to titrated insulin glargine40 weeksn = 546

    ADA Presidents' Select Abstract: Efficacy and Safety of Orforglipron vs. Placebo Added to Titrated Insulin Glargine in Adults with Long-Standing Type 2 Diabetes: ACHIEVE-5

    ADA Scientific Sessions 2026 abstract

  7. Orforglipron decreases HbA1c in humans (type 2 diabetes inadequately controlled with metformin; versus semaglutide 7 mg) (-0.48 percentage points versus semaglutide 7 mg (95% CI -0.65 to -0.31; p<0.0001)).

    “Estimated treatment differences were -0·48% (95% CI -0·65 to -0·31; p<0·0001) for orforglipron 12 mg versus semaglutide 7 mg”

    Human trialtype 2 diabetes inadequately controlled with metformin; versus semaglutide 7 mgoral12 mg once daily52 weeks

    Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial

    Lancet (London, England)

  8. Orforglipron decreases HbA1c in humans (type 2 diabetes and/or obesity; compared with placebo) (MD −1.07%, 95% CI −2.00 to −0.13).

    “Orforglipron reduced HbA1c (primary MD –1.07%, 95% CI –2.00 to –0.13;”

    Reviewtype 2 diabetes and/or obesity; compared with placebon = 2,672

    Cardiometabolic Efficacy and Safety of the Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron in Type 2 Diabetes and Obesity: A GRADE-Assessed Meta-Analysis and Trial Sequential Analysis with Subgroup Evaluation by Diabetic Status, Obesity Status, and Dose

    AHA Scientific Sessions 2026 abstract

  9. Orforglipron improves HbA1c in humans (overweight or obesity, with or without type 2 diabetes mellitus).

    “Improvements in glycated hemoglobin (HbA1c), fasting glucose, waist circumference, systolic blood pressure, triglycerides, and non-high-density lipoprotein cholesterol were also reported across several studies.”

    Reviewoverweight or obesity, with or without type 2 diabetes mellitus

    Efficacy and Safety of Oral Orforglipron for Weight Reduction in Adults With Overweight or Obesity: A Systematic Review

    Cureus

  10. Orforglipron decreases HbA1c in phase 3 trials.

    “Phase 3 trials demonstrated significant reductions in hemoglobin A1c, body weight, and cardiovascular risk markers”

    Reviewin phase 3 trials

    Orforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes

    American journal of nephrology

All 13

More on Orforglipron

Resistance training

downin humans9no changein humans2−0.6%

10 studies
  1. Resistance training decreases HbA1c in humans (type 2 diabetes).

    “Additionally, a significant reduction in HbA1c was observed in the training group (P = 0.012)”

    Human trialtype 2 diabetes3 sessions per week, 40–75% of one repetition maximum8 weeksfemalesn = 14

    The Effect of Eight Weeks of Resistance Training on Serum Levels of Myostatin, Interleukin-1 Beta, Vascular Endothelial Growth Factor, and Nitrotyrosine-3, and Its Association with Inflammatory-Myokine Changes and Glycemic Control in Middle-Aged Women with Type 2 Diabetes

    Research SquarePreprint

  2. Resistance training decreases HbA1c in humans (MD = −0.41, 95% CI −0.62 to −0.20).

    “The meta-analysis suggested that elastic-band resistance training may reduce HbA1c in patients with T2DM.”

    Human trial12 weeks (11 trials), 16 weeks, 24 weeks, or 48 weeksn = 618

    Effects of elastic-band resistance training on glycemic control, muscle strength, and functional outcomes in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

    Frontiers in public health

  3. Resistance training decreases HbA1c in humans (type 2 diabetes mellitus) (MD = -0.41, 95% CI -0.62 to -0.20).

    “Elastic-band resistance training was associated with reductions in HbA1c (MD = -0.41, 95% CI -0.62 to -0.20)”

    Human trialtype 2 diabetes mellitus

    Effects of elastic-band resistance training on glycemic control, muscle strength, and functional outcomes in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

    Frontiers in public health

  4. Resistance training decreases HbA1c in Ex + VitD group.

    “Within-group analyses showed that the Ex + VitD group exhibited the greatest glycemic improvement, with HbA1c decreasing from 6.61 ± 0.60% to 6.48 ± 0.58% (Δ = −0.13 ± 0.20), fasting glucose from 7.37 ± 1.15 to 6.58 ± 1.10 mmol/L (Δ = −0.79 ± 0.56), insulin from 5.48 ± 4.24 to 3.52 ± 2.14μU/mL (Δ = ±3.55), and HOMA-IR from 1.80 ± 1.41 to 1.03 ± 0.66 (Δ = −0.77 ± 1.14”

    Human trialin Ex + VitD group12 weeksn = 15

    Combined Effects of Combined Resistance Exercise and Vitamin D Supplementation on Cardiometabolic Profiles and Functional Capacities in Elderly Women with Type 2 Diabetes

    Metabolites

  5. Resistance training decreases HbA1c in humans (MD = −0.51, 95% CrI [−0.86, −0.15]).

    “Resistance training involving approximately 1000 to 2100 repetitions per week represents an effective dose range capable of significantly improving HbA1c levels in overweight or obese patients with T2DM.”

    Human trialn = 633

    Optimal exercise dose for resistance training to improve HbA1c levels in overweight and obese patients with type 2 diabetes: a systematic review of randomized controlled trials and a Bayesian network meta-analysis

    Frontiers in physiology

  6. Resistance training decreases HbA1c in humans (overweight or obese type 2 diabetes) (MD = -0.51, 95% CrI [-0.86, -0.15]).

    “1,500 reps/week (MD = -0.51, 95% CrI [-0.86, -0.15])”

    Human trialoverweight or obese type 2 diabetes23 weeks

    Optimal exercise dose for resistance training to improve HbA1c levels in overweight and obese patients with type 2 diabetes: a systematic review of randomized controlled trials and a Bayesian network meta-analysis

    Frontiers in physiology

  7. Resistance training showed no clear effect on HbA1c in humans (older adults with type 2 diabetes and sarcopenia).

    “HbA1c showed no clear intervention-related change”

    Human trialolder adults with type 2 diabetes and sarcopenia24 weeks

    Strength gains waned in seniors with type 2 diabetes and muscle loss

    Acta diabetologica

  8. Resistance training decreases HbA1c in humans (type 2 diabetes mellitus) (-0.62%).

    “Resistance training also improved glycemic control, reducing hemoglobin A1c by -0.62% and HOMA-IR by -0.90”

    Human trialtype 2 diabetes mellitusn = 1,396

    The impact of resistance training on the Atherogenic index of plasma and cardiometabolic health-related indicators in middle-aged and older adults with type 2 diabetes: A systematic review and Meta-analysis

    Maturitas

  9. Resistance training decreases HbA1c in humans (type 2 diabetes mellitus and frailty) (β=-0.28, 95% CI -0.53% to -0.03%, p=0.03).

    “A1C (β=-0.28, 95% CI -0.53% to -0.03%; p=0.03)”

    Human trialtype 2 diabetes mellitus and frailty16 weeksn = 182

    Impact of Biological Sex on Physical Function After 16-Week Elastic-band Resistance Training Along With Diabetes Education in Older Men and Women With Type 2 Diabetes Mellitus and Frailty

    Canadian journal of diabetes

  10. Resistance training decreases HbA1c in humans (type 2 diabetes mellitus) (MD -0.62, 95% CI -0.93 to -0.30).

    “HIRT; MD - 0.62, 95% CI - 0.93 to -0.30), low-certainty evidence indicated that moderate-intensity aerobic training (MIAT; MD - 0.58, 95% CI - 1.10 to -0.05)”

    Reviewtype 2 diabetes mellitus

    Comparative effects of different intensities of aerobic and resistance exercise on glycemic control and cardiorespiratory fitness in middle-aged older patients with type 2 diabetes: a network meta-analysis

    Frontiers in public health

All 13

More on Resistance training

Dapagliflozin

downin humans6no changein humans3

9 studies
  1. Dapagliflozin showed no clear effect on HbA1c in humans (Kidney transplant recipients with post-transplant diabetes mellitus; versus standard care).

    “whereas HbA1c and tacrolimus trough concentrations were similar.”

    Human trialKidney transplant recipients with post-transplant diabetes mellitus; versus standard care10 mg daily54 weeks

    Dapagliflozin and 54-week kidney function in kidney transplant recipients with post-transplant diabetes mellitus: a randomized controlled trial

    Diabetes research and clinical practice

  2. Dapagliflozin decreases HbA1c in humans (as an adjunct to insulin).

    “Similarly, Group B demonstrated reductions of 23.6% in FBG, 25.1% in 2hPBG, and 24.9% in HbA1c.‌ FBG, 2hPBG and HbA1c reductions were significantly greater in Group B than in Group A, indicating superior blood glucose index control.”

    Human trialas an adjunct to insulin3 months post-dischargen = 90

    Dapagliflozin as an adjunct to insulin improves glycemic control, weight, and lipid profile with a superior safety profile in type 2 diabetes: a randomized trial

    Clinics (Sao Paulo, Brazil)

  3. Dapagliflozin decreases HbA1c in humans (adjunct to insulin in type 2 diabetes) (24.9% vs. 10.3%).

    “Reductions in Group B versus Group A were: HbA1c (24.9%vs. 10.3%)”

    Human trialadjunct to insulin in type 2 diabetes3 monthsn = 86

    Dapagliflozin as an adjunct to insulin improves glycemic control, weight, and lipid profile with a superior safety profile in type 2 diabetes: a randomized trial

    Clinics (Sao Paulo, Brazil)

  4. Dapagliflozin decreases HbA1c in humans (added to semaglutide, Period 2 (weeks 26 to 52), vs placebo) (-0.46% HbA1c vs placebo).

    “In Period 2, HbA1c was further reduced by 0.46% (95% CI -0.78, -0.14; p=0.003) by dapagliflozin vs placebo”

    Human trialadded to semaglutide, Period 2 (weeks 26 to 52), vs placebooral10 mg daily26 weeksn = 36

    Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide, and Dapagliflozin (TTT1): A Phase 3 Clinical Trial

    ADA Scientific Sessions 2026 abstract

  5. Dapagliflozin showed no clear effect on HbA1c in humans (fell by 0.8% in both groups).

    “HbA1c fell by 0.8% in both groups with no between-group difference (p = 0.887), although fasting plasma glucose, fasting insulin, and HOMA2 dropped significantly in dapagliflozin arm..”

    Human trial12 weeksn = 98

    Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial

    Cardiovascular diabetology

  6. Dapagliflozin showed no clear effect on HbA1c in humans (type 2 diabetes) (between-group p = 0.887).

    “glycemic control improved similarly in both groups (median [IQR] HbA1c change: -0.78 [0.11]% vs. -0.80 [0.10]%; between-group p = 0.887).”

    Human trialtype 2 diabetes12 weeksn = 96

    Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial

    Cardiovascular diabetology

  7. Dapagliflozin decreases HbA1c in humans (type 2 diabetes; compared with placebo) (-0.52 vs. 0.11; p = 0.012).

    “dapagliflozin resulted in reduction in liver MRI-PDFF (-3.7% vs. 0.5%, p = 0.001), body weight (-3.84 vs. -1.42 kg, p = 0.015), and HbA1c (-0.52 vs. 0.11, p = 0.012).”

    Human trialtype 2 diabetes; compared with placebo10 mg12 monthsn = 56

    Dapagliflozin-Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes

    Obesity (Silver Spring, Md.)

  8. Dapagliflozin showed no clear effect on HbA1c in humans.

    “This indicates that HbA1c levels decreased significantly throughout the treatment period regardless of the therapeutic regimen employed, yet no differences were observed between the three treatment groups in their efficacy or rate of HbA1c reduction.”

    Human trialn = 81

    The Impact of Different Oral Antidiabetic Drugs on Insulin Pump Intensive Therapy in Type 2 Diabetes Patients: A Clinical Study

    Journal of diabetes research

  9. Dapagliflozin is linked with lower HbA1c in humans (-0.91 ± 1.78% points).

    “HbA1c showed a reduction of 0.91 ± 1.78% points among 158 patients with paired HbA1c data (paired p < 0.001)”

    Humansn = 158

    Real-world utilization, safety, and observed clinical outcomes of dapagliflozin among Sudanese patients with heart failure: a multicenter retrospective cohort study

    Scientific reports

  10. Dapagliflozin is linked with lower HbA1c in humans (compared with matched controls, whose HbA1c fell from 8.18% to 7.80%) (8.10% to 7.10% vs 8.18% to 7.80% in controls).

    “HbA1c decreased from 8.10% (65 mmol/mol) to 7.10% (54 mmol/mol) in the dapagliflozin group”

    Humanscompared with matched controls, whose HbA1c fell from 8.18% to 7.80%10 mg/day12 monthsn = 30

    Effects of dapagliflozin on proteinuria, glycemic control, and treatment burden in diabetic kidney transplant recipients: a matched cohort study

    Acta diabetologica

All 11

More on Dapagliflozin

Exercise

downin humans7upin humans1−23% to −0.4%

8 studies
  1. Exercise decreases HbA1c in humans (d = 1.02).

    “Glycemic indices were significantly improved with a reduction of fasting glucose of 12.82mg/dl and a reduction in the HbA1c of 0.42 percentage points, which practically shifted the group mean to the normoglycemic range (HbA1c 5.76%).”

    Human trial12 weeksmalesn = 30

    Exercise as a Non-Drug Intervention to Improve Body Composition and Cardiometabolic Health in Middle-Aged Saudi Men: A Community-Based Study in Al-Ahsa

    Research SquarePreprint

  2. Exercise decreases HbA1c in humans (sedentary, overweight or obese men) (-0.42%).

    “fasting glucose (−12.82 mg/dL), and HbA1c (−0.42%) (all p ≤ 0.002).”

    Human trialsedentary, overweight or obese men12 weeksmalesn = 15

    Exercise as a Non-Drug Intervention to Improve Body Composition and Cardiometabolic Health in Middle-Aged Saudi Men: A Community-Based Study in Al-Ahsa

    Research SquarePreprint

  3. Exercise improves HbA1c in adults with type 2 diabetes (from 72% to 79% (P=0.02)).

    “The proportion of individuals achieving targets increased from 72% to 79% (P=0.02) for A1c”

    Human trialin adults with type 2 diabetes12-week

    Movement Breaks Improve Cardiovascular Risk Factors in Adults Living with Type 2 Diabetes: A Randomized Trial

    ADA Scientific Sessions 2026 abstract

  4. Exercise decreases HbA1c in humans (young-onset T2DM) (F = 8.23, p < 0.001).

    “also in HbA1c (F = 8.23, p <0.001) and FBG (F = 3.44, p <0.034) after 12 and 24 weeks, respectively.”

    Human trialyoung-onset T2DM12-weekn = 84

    Effects of an exercise-based program on neutrophil-lymphocyte ratio and glycemic control in individuals with young-onset diabetes: a randomized controlled trial

    Current medical research and opinion

  5. Exercise decreases HbA1c in humans (metabolic syndrome) (-22.8%).

    “After 3 months, the CT group showed significant improvements compared to controls in blood glucose (-36.4%), HbA1c (-22.8%), HOMA-IR (-12.5%)”

    Human trialmetabolic syndrome3 monthsfemales

    Twenty-four weeks of combined exercise training prevents metabolic syndrome progression in adult women: evidence from a randomized controlled trial

    Biology of sport

  6. Exercise decreases HbA1c in humans (type 2 diabetes; compared with nonexercise control) (−0.32 percentage points).

    “HbA1c was reduced by 0.32 percentage points (seven trials; I 2 = 0%)”

    Reviewtype 2 diabetes; compared with nonexercise controlstructured exercise≥ 4 weeks

    Effect of Exercise Interventions on Sarcopenia‐Related Outcomes in Older Adults With Type 2 Diabetes: A Systematic Review and Meta‐Analysis

    Geriatrics & gerontology international

  7. Exercise decreases HbA1c in humans (long-term studies) (MD -0.11%, 95% CI -0.19 to -0.03).

    “morning training was associated with a greater reduction in HbA1c (mean difference [MD] - 0.11%, 95% confidence intervals [CI] - 0.19 to - 0.03, I2 = 0%, p = 0.009)”

    Reviewlong-term studies

    Influence of Morning and Afternoon Exercise on Body Composition and Metabolic Health: A Systematic Review and Meta-Analysis

    Sports medicine - open

  8. Exercise decreases HbA1c in humans (adults with type 1 diabetes) (MD -0.39 (-0.64, -0.15), P=0.002).

    “exercise training had a statistically significant reduction in HbA1c [mean difference (MD), confidence interval (CI)]: -0.39 (-0.64, -0.15), P=0.002, I2=0%”

    Reviewadults with type 1 diabetes

    Effect of Exercise-Based Interventions on HbA1c in Adults with Type 1 Diabetes: A Systematic Review and Meta-Analysis

    Cell journal

  9. Exercise decreases HbA1c in patients with type 1 diabetes (WMD = -0.52, 95% CI = [-0.74, -0.29]).

    “Results showed exercise had significant effect on reducing Glycated Hemoglobin (HbA1c) (WMD = -0.52; 95% CI = [-0.74, -0.29]).”

    Reviewin patients with type 1 diabetesn = 452

    Effect of Exercise Based on American College of Sports Medicine Recommendations on Glycemic Management in Patients with Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Diabetes, metabolic syndrome and obesity : targets and therapy

More on Exercise

Time-restricted feeding

downin humans7no changein humans1−0.8%

8 studies
  1. Time-restricted feeding decreases HbA1c in veterans with spinal cord injury and obesity (-0.2 ± 0.1%).

    “Twenty-four-hour glucose levels decreased by 7 ± 3 mg/dL (p = 0.02) and the GMI decreased by 0.2 ± 0.1% (p = 0.02), both with large effect sizes (d ~0.8).”

    Human trialin veterans with spinal cord injury and obesity6-week

    Time-Restricted Eating Is Feasible and Acceptable and Improves Glycemic Control in Veterans with Spinal Cord Injury and Obesity: A Pilot Trial

    Nutrients

  2. Time-restricted feeding decreases HbA1c in humans (veterans with spinal cord injury and obesity) (-0.2 ± 0.1%, p = 0.02).

    “Glucose Management Indicator (GMI), which estimates average HbA1c levels (-0.2 ± 0.1%, p = 0.02)”

    Human trialveterans with spinal cord injury and obesity6-weekn = 14

    Time-Restricted Eating Is Feasible and Acceptable and Improves Glycemic Control in Veterans with Spinal Cord Injury and Obesity: A Pilot Trial

    Nutrients

  3. Time-restricted feeding decreases HbA1c in humans (compared with general diet in overweight or obese adults with type 2 diabetes) (MD = -0.55, 95% CI: -0.77 to -0.33).

    “Compared with GD, TRE significantly reduced HbA1c (MD = -0.55, 95% CI: -0.77 to -0.33) and total cholesterol (MD = -0.17 mmol/L, 95% CI: -0.19 to -0.14).”

    Human trialcompared with general diet in overweight or obese adults with type 2 diabetesn = 805

    Comparative efficacy of dietary interventions for overweight or obese adults with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials

    Frontiers in nutrition

  4. Time-restricted feeding decreases HbA1c in humans.

    “Following 3 months of TRE (target: 10 hours, 9:00 am-7:00 pm), her eating window was shortened to 9.86 hours (9:03 am - 6:55 pm), and her HbA1c decreased from 7.7% to 7.3%.”

    Human trial3 months

    Time-restricted eating in adults with type 2 diabetes mellitus on concomitant glucagon-like peptide-1 receptor agonists: case report

    Frontiers in clinical diabetes and healthcare

  5. Time-restricted feeding decreases HbA1c in humans (compared to the CR group in adults with type 1 diabetes) (-0.46% [95% CI, -0.80, -0.12], P = 0.01).

    “HbA1c levels were significantly reduced by the TRE group when compared to the CR group (-0.46% [95% CI, -0.80, -0.12], P = 0.01).”

    Human trialcompared to the CR group in adults with type 1 diabeteseating only between 12-8 pm, without calorie counting6 monthsn = 32

    Effect of 8-Hour Time-Restricted Eating vs. Daily Calorie Restriction on Body Weight and Glycemic Control in Adults with Type 1 Diabetes

    ADA Scientific Sessions 2026 abstract

  6. Time-restricted feeding showed no clear effect on HbA1c in humans (MD 0.04%, 95% CI -0.20 to 0.27).

    “No significant between-group differences were observed for HbA1c (MD 0.04%, 95% CI -0.20 to 0.27; P=0.75; I 2 =0%)”

    ReviewCompared with caloric restriction in adults with overweight, obesity, or cardiometabolic risk factors4–52 weeks

    Time-Restricted Eating versus Calorie Restriction for Cardiometabolic Risk Reduction: A Systematic Review and Meta-Analysis

    AHA Scientific Sessions 2026 abstract

  7. Time-restricted feeding decreases HbA1c in one longitudinal cohort (-0.78%).

    “A persistent HbA1c reduction of -0.78% at 18 months in one longitudinal cohort suggested that glycemic benefits may compound with sustained adherence.”

    Reviewin one longitudinal cohort18 months

    Effects of Time-Restricted Eating on Insulin Sensitivity, Glycemic Control, and Metabolic Outcomes in Low- and Middle-Income Countries: A Systematic Review

    Clinical medicine insights. Endocrinology and diabetes

  8. Time-restricted feeding decreases HbA1c in humans (type 2 diabetes) (MD: -0.32%, 95% CI: -0.47 to -0.18).

    “TRE significantly reduced HbA1c (MD: -0.32%, 95% CI: -0.47 to -0.18) and fasting blood glucose (MD: -0.44 mmol/L, 95% CI: -0.68 to -0.19).”

    Reviewtype 2 diabetes

    Effects of time-restricted eating on people with type 2 diabetes: a systematic review and meta-analysis

    Diabetology & metabolic syndrome

  9. Time-restricted feeding decreases HbA1c in humans (compared with control) (WMD: -0.25% (95% CI -0.44 to -0.05)).

    “HbA1c (%) [WMD: -0.25% (95% CI -0.44 to -0.05), p = 0.01]”

    Reviewcompared with control

    Efficacy of different types of intermittent fasting in improving glycemic control in adults with overweight or obesity: a systematic review and network meta-analysis

    Reviews in endocrine & metabolic disorders

More on Time-restricted feeding

High-intensity interval training

downin humans6

6 studies
  1. High-intensity interval training decreases HbA1c in humans.

    “For the primary outcome, HbA1c levels decreased significantly from baseline to post-intervention in both the HIIT and MICT groups (both p = 0.001).”

    Human trial12 weeksn = 12

    Effects of High-Intensity Interval Versus Moderate-Intensity Continuous Training in Adults with Prediabetes: A Single-Blind Randomized Controlled Trial

    Journal of clinical medicine

  2. High-intensity interval training decreases HbA1c in bypass surgery patients (mean reduction of 7.71%).

    “with the HIIT-bypass group showing significant improvements in HbA1c, insulin, and FBS (mean reduction of 7.71%, 24.98%, and 6.34%, respectively; p < .05).”

    Human trialin bypass surgery patients8 weeksfemalesn = 20

    Impact of high-intensity interval training vs. moderate-intensity continuous training combined with strength training on physical and metabolic outcomes in post-bariatric surgery patients with sarcopenic obesity

    BMC musculoskeletal disorders

  3. High-intensity interval training decreases HbA1c in older adults with T2DM (MD = -0.95%).

    “HIIT demonstrated the largest estimated reduction (MD = -0.95%; 95% CrI -1.45, -0.49)”

    Reviewin older adults with T2DM

    Optimal dose and exercise modality to improve HbA1c in older adults with type 2 diabetes mellitus: a systematic review with pairwise, network, and dose-response meta-analyses

    Diabetes research and clinical practice

  4. High-intensity interval training decreases HbA1c in humans (type 2 diabetes mellitus) (MD = −1.02% (95% CrI −1.48, −0.59)).

    “high-intensity interval training (HIIT) produced the largest HbA1c reduction versus minimal-intervention control (MD = −1.02%; 95% CrI −1.48, −0.59).”

    Reviewtype 2 diabetes mellitus

    Optimal Dose and Exercise Modality to Improve Glycemic Control in Older Adults with Type 2 Diabetes: A Systematic Review and Network Meta-analysis

    ADA Scientific Sessions 2026 abstract

  5. High-intensity interval training decreases HbA1c in humans (type 2 diabetes mellitus; compared with control) (-0.70 percentage points (95% CI -0.88 to -0.51)).

    “and reduced glycosylated hemoglobin by 0.70% (95% confidence interval -0.88 to -0.51).”

    Reviewtype 2 diabetes mellitus; compared with control

    Effects of high-intensity interval training on cardiorespiratory fitness and metabolic outcomes in type 2 diabetes: A systematic review and meta-analysis

    Clinical rehabilitation

  6. High-intensity interval training decreases HbA1c in humans (adults with type 1 diabetes) (MD -0.24 (-0.45, -0.02), P=0.03).

    “statistically significant effect of high-intensity interval training (HIIT) on HbA1c levels in both the within-group analyses [MD: -0.24 (-0.45, -0.02), P=0.03, I2=0%]”

    Reviewadults with type 1 diabetes

    Effect of Exercise-Based Interventions on HbA1c in Adults with Type 1 Diabetes: A Systematic Review and Meta-Analysis

    Cell journal

More on High-intensity interval training

Metformin

downin humans5

5 studies
  1. Metformin decreases HbA1c in humans (Prediabetes and body mass index ≥23 kg/m2).

    “a significant reduction in HbA1c was observed only in the MET group.”

    Human trialPrediabetes and body mass index ≥23 kg/m26 monthsn = 217

    Effects of a 6-Month Intervention on Body Weight and Cardiometabolic Parameters Based on the Korean Diabetes Prevention Study

    Diabetes & metabolism journal

  2. Metformin is linked with lower HbA1c in humans (Newly diagnosed type 2 diabetes mellitus; no prior oral hypoglycemic medication) (6.85% versus 7.29% at baseline).

    “The HbA1c level significantly reduced after the 12-week treatment period (6.85% vs 7.29% at baseline, P = .001).”

    HumansNewly diagnosed type 2 diabetes mellitus; no prior oral hypoglycemic medication12 weeksn = 68

    Effectiveness of metformin as initial treatment on the metabolic profile of Saudi patients newly diagnosed with type 2 diabetes mellitus: A prospective observational study

    Medicine

  3. Metformin is linked with lower HbA1c in humans (newly diagnosed type 2 diabetes) (median 7.8 to 7.2; p = 0.001).

    “The HbA1c level decreased from 7.8 (6.9-8.9) to 7.2 (6.5-8.1) (p = 0.001).”

    Humansnewly diagnosed type 2 diabetessix monthsn = 52

    Assessing Cognitive Responses and Serum Vitamin B₁₂ Levels in Newly Diagnosed Type 2 Diabetes Mellitus Patients Treated With Metformin: A Prospective Study

    Cureus

  4. Metformin is linked with lower HbA1c in humans (at imeglimin initiation in type 2 diabetes) (adjusted difference -0.57%, 95% CI -0.88 to -0.26).

    “Metformin continuation remained associated with greater adjusted HbA1c reduction in sensitivity ANCOVA (adjusted difference - 0.57%, 95% CI - 0.88 to - 0.26; P = 0.0006).”

    Humansat imeglimin initiation in type 2 diabetes24 weeksn = 70

    Effect of metformin dose reduction versus continuation at imeglimin initiation on glycemic control in type 2 diabetes: a retrospective real-world analysis

    Acta diabetologica

  5. Metformin decreases HbA1c in humans (MD -0.070%).

    “At 12 months, metformin significantly reduced waist circumference (MD -1.12 cm; p = 0.014), HbA1c (MD -0.070%; p = 0.029)”

    ReviewAdded to androgen-deprivation therapy in prostate cancer, versus androgen-deprivation therapy alone12 months

    Metabolic and oncological effects of metformin added to ADT in prostate cancer: systematic review and meta-analysis including STAMPEDE

    Prostate cancer and prostatic diseases

More on Metformin

Liraglutide

downin humans4−0.3%

4 studies
  1. Liraglutide decreases HbA1c in humans (median -2.5% (range, 1.1–3.1%)).

    “After 12 weeks of therapy, the median HbA1c decreased by 2.5% (27 mmol/mol; range, 1.1–3.1% [12–34 mmol/mol]; p = 0.012”

    Human trial12 weeksn = 5

    Liraglutide use in congenital generalized lipodystrophy: glycemic and metabolic outcomes

    Frontiers in endocrinology

  2. Liraglutide decreases HbA1c in humans (congenital generalized lipodystrophy; treatment completers) (Median change, -2.5%).

    “liraglutide significantly reduced HbA1c (median change, -2.5%; p=0.012)”

    Human trialcongenital generalized lipodystrophy; treatment completers1.8 mg/day12 weeksn = 5

    Liraglutide use in congenital generalized lipodystrophy: glycemic and metabolic outcomes

    Frontiers in endocrinology

  3. Liraglutide decreases HbA1c in humans.

    “compared with controls, the total effective rate of the research group was increased, Ca, BALP and SFRP5 were elevated and the post-medication P, β-CTX, GM indices, glycemic variability parameters and inflammatory markers were decreased”

    Human trialin diabetic osteoporosis patients receiving zoledronic acid and calcium carbonate and vitamin D3n = 99

    Liraglutide in combination with zoledronic acid and calcium carbonate and vitamin D3 for diabetic osteoporosis: efficacy and glycometabolism impact

    American journal of translational research

  4. Liraglutide is linked with lower HbA1c in humans (Type 2 diabetes and obesity; compared with SGLT-2 inhibitors) (0.4% greater HbA1c reduction (95% CI: 0.3–0.5)).

    “liraglutide and dulaglutide provided superior glycaemic control and similar weight reduction over 5 years”

    HumansType 2 diabetes and obesity; compared with SGLT-2 inhibitors18 months; advantage maintained throughout follow-upn = 4,296

    Effectiveness of <scp>GLP</scp> ‐1 <scp>RAs</scp> and <scp>SGLT</scp> ‐2is for Weight Loss and Glycaemic Control: An Observational Emulation of a Target Trial

    Diabetes, obesity & metabolism

  5. Liraglutide decreases HbA1c in humans (versus glucose-lowering therapies (GLTs)) (-0.26%).

    “while liraglutide 1.8 mg reduced HbA1c by -0.26% versus GLTs”

    Reviewversus glucose-lowering therapies (GLTs)1.8 mg1.8 mg

    A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus

    Diabetes, metabolic syndrome and obesity : targets and therapy

More on Liraglutide

Icosema

downin humans3no changein humans1

4 studies
  1. Icosema showed no clear effect on HbA1c in humans (versus insulin-based intensification in adults inadequately controlled on basal insulin) (pooled MD -0.37%, 95% CI -0.95 to 0.21; I2=98%).

    “IcoSema showed no statistically significant difference in HbA1c reduction compared with control (pooled MD -0.37%, 95% CI -0.95 to 0.21; P = 0.21; I2=98%)”

    Human trialversus insulin-based intensification in adults inadequately controlled on basal insulin

    Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials

    Cardiovascular diabetology. Endocrinology reports

  2. Icosema decreases HbA1c in humans (versus once-daily insulin glargine U100) (ETD -0.88 percentage points (95% CI -1.12 to -0.63)).

    “mean change to week 40 was greater with IcoSema versus glargine U100 (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63])”

    Human trialversus once-daily insulin glargine U100once-weeklyweek 40n = 485

    Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial

    The lancet. Diabetes & endocrinology

  3. Icosema decreases HbA1c in humans (versus basal insulin alone) (-0.74 percentage points (95% CI -0.95 to -0.53)).

    “Against basal insulin alone (COMBINE 1 and 4; two trials, 1,776 participants), IcoSema lowered HbA1c by 0.74 percentage points (95% confidence interval (CI) -0.95 to -0.53; I2 = 63%)”

    Reviewversus basal insulin alonen = 1,776

    IcoSema in Weight Management and Glycaemic Control: A Systematic Review and Meta-Analysis

    Cureus

  4. Icosema decreases HbA1c in humans (compared with IDegLira) (-0.4% (95% CrI -0.56, -0.24)).

    “compared with IDegLira, IcoSema was associated with significantly greater HbA1c reduction (- 0.4%; 95% credible interval [CrI] - 0.56, - 0.24)”

    Reviewcompared with IDegLira52 weeks

    Efficacy and Safety of Once-Weekly IcoSema Versus Once-Daily IDegLira in People with Type 2 Diabetes: Systematic Literature Review and Network Meta-analysis

    Diabetes therapy : research, treatment and education of diabetes and related disorders

More on Icosema

Combined aerobic and resistance training

downin humans4

4 studies
  1. Combined aerobic and resistance training decreases HbA1c in humans (older adults with type 2 diabetes mellitus) (MD = -1.05%).

    “For HbA1c, CE (MD = -1.05%; 95% CrI: -1.43, -0.64), TCS (MD = -0.80%; 95% CrI: -1.09, -0.52), HIIT (MD = -0.63%; 95% CrI: -1.07, -0.19)”

    Human trialolder adults with type 2 diabetes mellitus

    The optimal exercise modality and dose for glycemic control in older adults with type 2 diabetes mellitus: a systematic review and network meta-analysis

    Frontiers in endocrinology

  2. Combined aerobic and resistance training decreases HbA1c in older adults with T2DM (MD = -0.59%).

    “followed by CE (MD = -0.59%; 95% CrI -0.93, -0.25)”

    Reviewin older adults with T2DM

    Optimal dose and exercise modality to improve HbA1c in older adults with type 2 diabetes mellitus: a systematic review with pairwise, network, and dose-response meta-analyses

    Diabetes research and clinical practice

  3. Combined aerobic and resistance training decreases HbA1c in humans (compared with control conditions) (Hedges' g = -0.44, p < 0.01).

    “Compared with control conditions, combined training significantly improved HbA1c (Hedges' g = -0.44, p < 0.01)”

    Reviewcompared with control conditionsn = 1,853

    Effects of combined training on glycemic control and lipid profiles in middle-aged and older adults: A three-level meta-analysis of randomized controlled trials

    Maturitas

  4. Combined aerobic and resistance training decreases HbA1c in humans (type 2 diabetes mellitus) (MD = −0.60% (95% CrI −0.94, −0.26)).

    “combined exercise (CE) (MD = −0.60%; 95% CrI −0.94, −0.26)”

    Reviewtype 2 diabetes mellitus

    Optimal Dose and Exercise Modality to Improve Glycemic Control in Older Adults with Type 2 Diabetes: A Systematic Review and Network Meta-analysis

    ADA Scientific Sessions 2026 abstract

More on Combined aerobic and resistance training

Physical activity

downin humans3no changein humans1

3 studies
  1. Physical activity decreases HbA1c in humans (−1.18% vs −0.57%).

    “HbA1c dropped by 0.57% in the control group, with a greater 1.18% reduction (95% CI, −1.65, −0.71) in the intervention group (ηp2 = 0.179).”

    Human trial12 weeksn = 28

    Effects of a device-measured physical activity intervention on visual outcomes, including contrast sensitivity, and glycaemic control in individuals with abnormal glucose tolerance: a pilot randomised trial post-CarMeR study

    Pilot and feasibility studies

  2. Physical activity decreases HbA1c in humans (newly diagnosed with AGT) (-1.18% (95% CI, -1.65, -0.71)).

    “participants in the intervention group demonstrated a 1.18% reduction in HbA1c (95% CI, -1.65, -0.71)”

    Human trialnewly diagnosed with AGTaverage of 77 min daily12-week

    Effects of a device-measured physical activity intervention on visual outcomes, including contrast sensitivity, and glycaemic control in individuals with abnormal glucose tolerance: a pilot randomised trial post-CarMeR study

    Pilot and feasibility studies

  3. Physical activity showed no clear effect on HbA1c in humans (β = −0.39%, 95% CI: - 1.6 to 0.8).

    “The interaction for HbA1c (β = −0.39%, 95% CI: - 1.6 to 0.8) suggested a modest differential change, while time effects for both FPG ((β = −11.1, 95% CI: −17.1 to −5.1) and HbA1c (β = −1.7%, 95% CI: −2.6 to −0.7) pointed toward reductions in glycemic levels across both groups”

    Human trial12-weekn = 28

    Efficacy of device-measured physical activity on cardiometabolic outcomes among individuals with abnormal glucose tolerance in Ghana: A pilot randomized controlled trial

    Global epidemiology

  4. Physical activity decreases HbA1c in humans (abnormal glucose tolerance) (-1.2% vs. -0.6%).

    “The intervention group was associated with larger within-group changes in HbA1c (-1.2% vs. -0.6%)”

    Human trialabnormal glucose tolerance12-weekn = 28

    Efficacy of device-measured physical activity on cardiometabolic outcomes among individuals with abnormal glucose tolerance in Ghana: A pilot randomized controlled trial

    Global epidemiology

  5. Physical activity is linked with lower HbA1c in people with type 2 diabetes (6.84% vs. 8.07%, p<0.0001).

    “Physically active participants exhibited lower HbA1c (6.84% vs. 8.07%, p<0.0001)”

    Humansin people with type 2 diabetesn = 185

    DIFFERENTIAL ASSOCIATIONS BETWEEN PHYSICAL ACTIVITY AND GLYCEMIC CONTROL ACROSS BODY MASS INDEX IN TYPE 2 DIABETES: A COMPARATIVE ANALYSIS OF HBA1C AND FRUCTOSAMINE

    Georgian medical news

More on Physical activity

All 218

Effects

32

Mortality

mediatesin humans2no changein humans2

4 studies
  1. HbA1c is linked with mortality in dynapenic obesity-mortality association (13.7% (P = 0.006)).

    “SII and HbA1c statistically explained 5.8% (P = 0.041) and 13.7% (P = 0.006), respectively, of the observed dynapenic obesity-mortality association.”

    Humansin dynapenic obesity-mortality associationn = 5,674

    Association of dynapenic obesity defined by sagittal abdominal diameter and relative grip strength with all-cause mortality: a prospective cohort study

    Archives of gerontology and geriatrics

  2. HbA1c is linked with mortality in humans (association between cumulative RCII burden and all-cause mortality) (4.61% of the effect).

    “Mediation analyses indicated that Cystatin C and HbA1c significantly mediated this association, accounting for 10.71% and 4.61% of the effect, respectively.”

    Humansassociation between cumulative RCII burden and all-cause mortalityn = 6,977

    Longitudinal Trajectories and Cumulative Burden of Remnant Cholesterol Inflammatory Index and Mortality Risk

    Geriatrics & gerontology international

  3. HbA1c was not clearly linked with mortality in acute coronary syndrome patients (2.0% vs 1.6% vs 2.9%, p = 0.294).

    “In-hospital mortality showed a gradual increase across these groups: 2.0% in non-diabetics, 1.6% in pre-diabetics, and 2.9% in diabetics (p = 0.294).”

    Humansin acute coronary syndrome patientsin-hospitaln = 2,772

    Prediabetes in acute coronary syndrome: an overlooked predictor of adverse outcomes

    Frontiers in clinical diabetes and healthcare

  4. HbA1c was not clearly linked with mortality in humans (hospitalized patients with type 2 diabetes) (p = 0.615).

    “HbA1c levels were not significantly associated with mortality (p = 0.615).”

    Humanshospitalized patients with type 2 diabetesn = 372

    Investigation of the Relationship Between Glycemic Control and Inflammation-Nutrition Indices in Older Adults with Type 2 Diabetes

    Medicina (Kaunas, Lithuania)

Type 2 diabetes

mediatesin humans2

2 studies
  1. HbA1c is linked with type 2 diabetes in humans (35.9%).

    “HbA1c mediated 35.9% of the total effect (p = 0.017)”

    Humansserum

    Fatty-acid patterns and odds of incident type 2 diabetes in South Asians: a causal mediation analysis within the CARRS cohort

    Diabetes research and clinical practice

  2. HbA1c is linked with type 2 diabetes in humans (conservative outcome definition) (13.7-27.5%).

    “Under the conservative outcome definition, HbA1c mediated 13.7-27.5% of the total effect”

    Humansconservative outcome definition

    Joint trajectories of adiposity and systemic inflammation and incident diabetes among older adults: a bi-cohort prospective study with mediation analysis

    Frontiers in nutrition

More on Type 2 diabetes

Cognitive function

downin humans2

2 studies
  1. HbA1c is linked with worse cognitive function in humans (type 1 diabetes) (β = -0.47, p < 0.001).

    “higher HbA1c (β = -0.47 and p < 0.001) and higher vibration perception threshold (β = -0.049 and p = 0.004) were independent predictors of lower cognitive performance.”

    Humanstype 1 diabetes

    Clinical and Metabolic Predictors of Cognitive Impairment in Type 1 Diabetes: The Role of Peripheral Neuropathy and Hypoglycaemia Unawareness. Findings From a HAD-1 Study

    Diabetes/metabolism research and reviews

  2. HbA1c is linked with worse cognitive function in humans.

    “Age and HbA1c were significantly inversely correlated with 3MS scores.”

    Humansn = 396

    Glycemic dysregulation and cognitive impairment in aging adults: a cross-sectional study with amyloid biomarker correlation

    Frontiers in aging

Cardiometabolic multimorbidity

mediatesin humans1

1 study
  1. HbA1c is linked with cardiometabolic multimorbidity in humans (48.44% of the association).

    “In CHARLS, exploratory mediation analysis estimated that HbA1c accounted for 48.44% of the association.”

    Humansexploratory mediation of the association between TyHGB and cardiometabolic multimorbidity in CHARLSn = 8,116

    Triglyceride–HDL cholesterol–glucose body index and cardiometabolic multimorbidity: evidence from a national longitudinal cohort and a subplateau health-screening population

    Frontiers in endocrinology

More on Cardiometabolic multimorbidity

8-hydroxy-2'-deoxyguanosine

no changein humans1

1 study
  1. HbA1c was not clearly linked with 8-hydroxy-2'-deoxyguanosine in humans (patient subgroups defined by HbA1c).

    “Stratification of patients according to HbA1c levels revealed no statistically significant differences in 8-OHdG concentrations among the subgroups.”

    Humanspatient subgroups defined by HbA1cplasma

    Plasma 8-Hydroxy-2′-Deoxyguanosine Levels in Patients with Type 2 Diabetes Mellitus

    Diagnostics (Basel, Switzerland)

More on 8-hydroxy-2'-deoxyguanosine

Brain 18F-FDG uptake

no changein humans1

1 study
  1. HbA1c was not clearly linked with brain 18F-FDG uptake in humans.

    “Linear regression to HbA1c showed a negative correlation to 18F-FDG uptake in frontal and parietal cortical subregions, but no correlation to temporal lobe uptake.”

    Humanstemporal lobe

    Effect of metformin treatment on brain 18F-FDG uptake: a translational study

    Frontiers in radiology

More on Brain 18F-FDG uptake

High-sensitivity cardiac troponin T

no changein humans1

1 study
  1. HbA1c was not clearly linked with high-sensitivity cardiac troponin T in people with prediabetes (r = -0.053).

    “No significant association was found between hs-cTnT values and HbA1c levels (Spearman's r = -0.053; p = 0.602).”

    Humansin people with prediabetes

    Evaluation of biochemical evidence suggestive of subclinical myocardial injury using high-sensitivity cardiac troponin T in patients with prediabetes: a cross-sectional study

    PeerJ

More on High-sensitivity cardiac troponin T

Cardiometabolic disease

mediatesin humans1

1 study
  1. HbA1c is linked with cardiometabolic disease in humans (between preference-intake discordance and CMD).

    “HbA1c was a consistent positive mediator”

    Humansbetween preference-intake discordance and CMDn = 168,163

    Meat Preference–Intake Discordance and Incident Cardiometabolic Disease in UK Biobank: A Prospective Cohort Study

    Research SquarePreprint

More on Cardiometabolic disease

Early weight-loss response

no changein humans1

1 study
  1. HbA1c was not clearly linked with early weight-loss response in humans (baseline glycemic characteristics).

    “rather than with baseline glycemic or hemodynamic characteristics”

    Humansbaseline glycemic characteristics

    Oral GLP-1 Super-Responders are Characterized by Greater Pretreatment Weight Gain, Faster Early Dose Escalation, and Larger On-Treatment Blood Pressure Reductions

    Preprints.orgPreprint

Cardiometabolic multiple long-term conditions risk discrimination

upin humans1

1 study
  1. HbA1c is linked with better cardiometabolic multiple long-term conditions risk discrimination in humans (added to established risk factors) (ΔC-index=0.0344, P<.001).

    “Adding HbA1c to established risk factors improved discrimination (ΔC-index=0.0344, P<.001)”

    Humansadded to established risk factors12-15 yearsn = 2,233

    Glycemic Markers and Cardiometabolic Multiple Long-Term Conditions: Comparative Roles of Glycated Hemoglobin and Fasting Plasma Glucose in the English Longitudinal Study of Ageing

    Mayo Clinic proceedings. Innovations, quality & outcomes

All 32

Upstream

13

DNAm PAI-1

mediatesin humans1

1 study
  1. DNAm PAI-1 is linked with HbA1c in humans (28.8% of association mediated; FDR p=0.038).

    “DNAm PAI-1 mediated 30.0% of the association with IL-6 (N=232; FDR p=0.030) and 28.8% of the association with HbA1c (N=227; FDR p=0.038).”

    HumansAssociation of neighborhood building conditions rated fair or below with HbA1c; adjusted for sex and self-reported racen = 227

    Epigenetic Mediation of Early-Life Exposures and Young-Adult Cardiometabolic Risk in the Future of Families and Child Wellbeing Study

    AHA Scientific Sessions 2026 abstract

More on DNAm PAI-1

Body mass index

no changein humans1

1 study
  1. Body mass index was not clearly linked with HbA1c in humans (type 2 diabetes mellitus; comparison across BMI groups) (mean HbA1c ∼ 8.2-8.4% across BMI groups).

    “Glycemic control (mean HbA1c ∼ 8.2-8.4%) was similar among BMI groups.”

    Humanstype 2 diabetes mellitus; comparison across BMI groupsn = 6,530

    Impact of BMI on Ramadan fasting in individuals with type 2 diabetes mellitus: Insights from the DaR Global Surveys 2020-2022

    Journal of Taibah University Medical Sciences

More on Body mass index

Anxiety

downin humans1

1 study
  1. Anxiety is linked with lower HbA1c in humans (diabetes in older adults) (β = -0.43, p = 0.003).

    “anxiety (β = -0.43, p = 0.003)”

    Humansdiabetes in older adults

    Homebound status and glycemic control among older adults: results from a national survey

    GeroScience

More on Anxiety

Depression

upin humans1

1 study
  1. Depression is linked with higher HbA1c in humans (diabetes in older adults) (β = + 0.62, p < .001).

    “depression (β = + 0.62, p < .001)”

    Humansdiabetes in older adults

    Homebound status and glycemic control among older adults: results from a national survey

    GeroScience

More on Depression

Homebound status

no changein humans1

1 study
  1. Homebound status was not clearly linked with HbA1c in humans (diabetes).

    “Homebound status was not independently associated with HbA1c in adjusted models.”

    Humansdiabetes

    Homebound status and glycemic control among older adults: results from a national survey

    GeroScience

Second-line glucose-lowering therapy

downin humans1

1 study
  1. second-line glucose-lowering therapy is linked with lower HbA1c in humans (adults aged 70 or younger, 12-month outcome, trend 2019 to 2023) (-11.3 to -12.9 mmol/mol).

    “mean 12-month HbA1c response improved from -11.3 mmol/mol (95% CI: -11.6 to -11.0) in 2019 to -12.9 mmol/mol”

    Humansadults aged 70 or younger, 12-month outcome, trend 2019 to 202312 monthsn = 84,589

    Trends in Second-Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population-Based Study, 2019-2024

    Diabetes, obesity & metabolism

Depressive symptoms

no changein humans1

1 study
  1. Depressive symptoms were not clearly linked with HbA1c in humans (Chinese middle-aged and older adults) (β2 = 0.001 (95% CI -0.005 to 0.003, p = 0.6442)).

    “path coefficient from baseline CES-D to follow-up HbA1c (β2, 0.001; 95% CI, -0.005 to 0.003; p = 0.6442)”

    HumansChinese middle-aged and older adultsn = 7,124

    Temporal Association Between Diabetes and Depression and Their Impact on Cardiovascular Disease in Chinese Older Adults

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

More on Depressive symptoms

Vitamin D deficiency

no changein humans1

1 study
  1. vitamin D deficiency was not clearly linked with HbA1c in humans (type 2 diabetes mellitus).

    “but not with fasting plasma glucose or HbA1c.”

    Humanstype 2 diabetes mellitusn = 302

    Association between vitamin D deficiency and sarcopenia in older adults with type 2 diabetes

    Vietnam Journal of Diabetes and Endocrinology

PIEZO1

downin humans1

1 study
  1. PIEZO1 is linked with lower HbA1c in humans (additive genetic model).

    “PIEZO1 rs563555492 T was associated with erythrocytic traits and lower HbA1c”

    Humansadditive genetic model

    An ancestry-enriched PIEZO1 missense variant biases HbA1c-based diagnosis of prediabetes and type 2 diabetes in South Asians

    medRxivPreprint

More on PIEZO1

HBB

upin humans1

1 study
  1. HBB is linked with higher HbA1c in humans (rs33950507 heterozygous carriers) (beta=0.13, 95%CI:0.08-0.18, p=7.8x10-8).

    “rs33950507, a common variant causal for HbE thalassaemia, was associated with increased HbA1c (beta=0.13, 95%CI:0.08-0.18, p=7.8x10-8)”

    Humansrs33950507 heterozygous carriers

    HbA1c-based diagnosis of type 2 diabetes and complication risk are distorted in British south Asians due to HbE thalassaemia trait

    medRxivPreprint

More on HBB

All 13

Associations

228

Mortality

upin humans7mixedin humans4downin humans3HR 0.71–1.43

14 studies
  1. HbA1c predicts mortality in humans (diabetes subgroup receiving maintenance hemodialysis; multivariable-adjusted) (Adjusted HR 1.43 per 1% higher HbA1c, 95% CI 1.17–1.76).

    “Within the diabetes subgroup, HbA1c was the strongest modifiable predictor (adjusted HR 1.43 per 1%, 95% CI 1.17–1.76, p < 0.001)”

    Humansdiabetes subgroup receiving maintenance hemodialysis; multivariable-adjusted68 monthsn = 126

    Diabetes and all-cause mortality in hemodialysis: A comparative survival analysis with complementary machine-learning methods

    PloS one

  2. HbA1c is associated with mortality in humans (Patients without previously diagnosed diabetes who underwent coronary angiography).

    “HbA1c showed a U-shaped association with fatal outcomes, namely cardiovascular death and all-cause mortality”

    HumansPatients without previously diagnosed diabetes who underwent coronary angiographyMedian follow-up 5.1 yearsn = 55,570

    Cardiovascular risk emerges below the diagnostic threshold for diabetes: insights from the Western Denmark Heart Registry

    ESC Congress 2026 abstract

  3. HbA1c is linked with a higher risk of mortality in humans (cystic fibrosis-related diabetes) (RR 1.41 (95% CI 1.15-1.73)).

    “Compared with HbA1c ≤42 mmol/mol, adjusted mortality rate ratios were 1.41 (95% CI 1.15-1.73) for HbA1c >42-53 mmol/mol”

    Humanscystic fibrosis-related diabetesn = 4,477

    Long-term Glycemia and Risk of Death in Cystic Fibrosis-Related Diabetes: A UK Cystic Fibrosis Registry Study

    Diabetes care

  4. HbA1c is associated with mortality in humans (Type 2 diabetes with a low incidence of severe hypoglycemia) (Suggested HbA1c target < 6.5%).

    “no clear lower threshold of the glycated hemoglobin associated with the lowest risk of myocardial infarction or all-cause mortality”

    HumansType 2 diabetes with a low incidence of severe hypoglycemia

    Search for the glycated hemoglobin target minimizing mortality among people with type 2 diabetes with rare incidence of treatment-related severe hypoglycemia - Epidemiologic analysis of J-DOIT3 randomized controlled trial

    PloS one

  5. HbA1c is associated with mortality in humans (Adults with diabetes; baseline HbA1c ≥ 7.0% versus < 7.0%) (Adjusted OR 2.28, 95% CI 1.15–4.59).

    “HbA1c ≥ 7.0% was associated with higher mortality odds than HbA1c < 7.0% (adjusted OR 2.28, 95% CI 1.15–4.59, P = 0.018).”

    HumansAdults with diabetes; baseline HbA1c ≥ 7.0% versus < 7.0%2011–2020n = 578

    Baseline HbA1c, subsequent frailty, and mortality among middle-aged and older adults with diabetes: a longitudinal cohort study

    Research SquarePreprint

  6. HbA1c is associated with mortality in humans (General population; U-shaped association).

    “We observed a significant non-linear U-shaped association between baseline HbA1c levels and mortality.”

    HumansGeneral population; U-shaped associationAverage follow-up of 99.7 ± 53.6 monthsn = 38,072

    Non-Linear U-Shaped Trend Associations between HbA1c and All-Cause and Cardiovascular Mortality

    Clinical laboratory

  7. HbA1c is linked with a higher risk of mortality in patients with type 2 diabetes on peritoneal dialysis (HR 1.18, 95% CI 1.03-1.35).

    “Compared with HbA1C≤8%, HbA1C>8% was associated with higher risk of all-cause mortality in the cohort as a whole (HR 1.18 p=0.02 95%CI 1.03-1.35)”

    Humansin patients with type 2 diabetes on peritoneal dialysis

    Association between Glycemic Control and Survival in Patients with Type 2 Diabetes on Peritoneal Dialysis: Results from the PDOPPS

    Clinical journal of the American Society of Nephrology : CJASN

  8. HbA1c predicts mortality in humans (HR 1.24 per 1 SD).

    “HbA1c (1.24) and albumin (0.81) carried most of the signal”

    Humansper 1 SDmedian 4.4 yearsn = 2,144

    Seven routine blood markers predict five-year mortality in older Indians: a risk score from the LASI-DAD cohort

    Research squarePreprint

  9. HbA1c is linked with a lower risk of mortality in humans (HR 0.71; 95% CI, 0.60-0.84).

    “reducing the risk of dementia (HR 0.64; 95% CI, 0.51-0.79) and mortality (HR 0.71; 95% CI, 0.60-0.84).”

    Humanstrajectory improvement in patients with Poor baseline control (≥9.0%) after SGLT2 inhibitor initiation

    HbA1c trajectories after SGLT2 inhibitor initiation and the risk of dementia

    Journal of Alzheimer's disease : JAD

  10. HbA1c is associated with mortality in humans across all frailty groups (lowest at HbA1c 48-57.9 mmol/mol).

    “All-cause mortality risk was lowest at HbA1c 48-57.9 mmol/mol and increased at both lower and higher HbA1c levels across all frailty groups.”

    Humansacross all frailty groups

    The use of the electronic frailty index to optimise HbA1c targets in older individuals with type 2 diabetes

    Age and ageing

All 14

Sarcopenia

upin humans6mixedin humans1OR 1.88–1.89

7 studies
  1. HbA1c is associated with sarcopenia in humans (Type 2 diabetes mellitus for at least 12 months; multivariable analysis) (aOR 1.567, 95% CI 1.004–2.445).

    “higher mean HbA1c (aOR 1.567, 95% CI: 1.004–2.445; p = 0.048) were associated with greater odds of sarcopenia”

    HumansType 2 diabetes mellitus for at least 12 months; multivariable analysisMean HbA1c over the preceding yearn = 100

    Sarcopenia in Middle-Aged Adults With Type 2 Diabetes Mellitus: Prevalence, Associated Factors and Relationship With Gonadal Hormones

    Research SquarePreprint

  2. Sarcopenia is associated with HbA1c in humans (male individuals with type 2 diabetes and clinically significant liver fibrosis) (8.8% vs. 7.9%, p = 0.007).

    “glycated hemoglobin (HbA1c, 8.8% vs. 7.9%, p = 0.007)”

    Humansmale individuals with type 2 diabetes and clinically significant liver fibrosismalesn = 131

    Sarcopenia in Indian Males Having Clinically Significant Liver Fibrosis in Type 2 Diabetes: A Tertiary-Centre Cross-Sectional Study to Estimate the Prevalence and Associated Factors

    Journal of frailty, sarcopenia and falls

  3. HbA1c is associated with sarcopenia in humans (HbA1c ≥ 7.0%) (aOR 3.24, 95% CI 1.42-7.40).

    “and those with HbA1c ≥ 7.0% (aOR 3.24, 95% CI 1.42-7.40)”

    HumansHbA1c ≥ 7.0%

    Glycated Hemoglobin, Lifestyle, and Sarcopenia in Rural Older Adults: A Cross-Sectional Analysis

    Nursing & health sciences

  4. HbA1c is linked with a higher risk of sarcopenia in humans (OR 1.89, 95% CI 1.16-3.08).

    “poor glycaemic control (HbA1c ≥ 7.0%; OR 1.89, 95% CI 1.16-3.08) were associated with higher odds of sarcopenia.”

    Humans

    Glycaemic Control, Blood Pressure and Lifestyle Behaviours in Relation to Sarcopenia Among Older Adults in Korea: A Population-Based Cross-Sectional Study

    Australasian journal on ageing

  5. HbA1c is associated with sarcopenia in humans.

    “associations with composite sarcopenia vary according to diagnostic frameworks and phenotype composition.”

    Reviewtype 2 diabetes mellitus; associations depend on diagnostic frameworks and phenotype compositionskeletal muscle

    HbA1c and skeletal muscle health in type 2 diabetes: phenotype-specific associations across different analytical directions and mechanistic insights

    Frontiers in endocrinology

  6. HbA1c is associated with sarcopenia in humans (patients with type 2 diabetes) (OR=1.88, 95%CI 1.36~2.60).

    “HbA1c (OR=1.88, 95%CI 1.36~2.60), sex (OR=1.61, 95%CI 1.34~1.92), duration of diabetes (OR=1.23, 95%CI 1.06~1.42), and diabetes complications (OR=4.22, 95%CI 3.29~5.41) were risk factors for sarcopenia”

    Reviewpatients with type 2 diabetes

    Systematic review of risk prediction models for sarcopenia in patients with type 2 diabetes

    Chinese Journal of Geriatric Care

  7. HbA1c is associated with sarcopenia in older patients with type 2 diabetes mellitus.

    “higher fasting blood glucose levels, higher HbA1c levels”

    Reviewin older patients with type 2 diabetes mellitus

    Factors associated with sarcopenia in elderly patients with type 2 diabetes mellitus

    Frontiers in endocrinology

More on Sarcopenia

Diabetes mellitus

upin humans3upin silico1

4 studies
  1. HbA1c predicts diabetes mellitus in humans (Optimal cut-off 6.1%: sensitivity 89.8%, specificity 86.9%; agreement κ = 0.76).

    “For diabetes, HbA1c ≥6.5% showed 75.9% sensitivity and 96.3% specificity, whereas the optimal cut-off was 6.1% (89.8% sensitivity, 86.9% specificity).”

    HumansDiagnostic classification relative to oral glucose tolerance test in participants without prior diabetesn = 376

    Beyond Global Cut-offs: The Predictive Value of Glycated Haemoglobin for Dysglycaemia in South Asia

    Indian journal of endocrinology and metabolism

  2. HbA1c predicts diabetes mellitus in humans (detection of diabetes mellitus) (AUC 0.86 (95% CI: 0.83-0.88)).

    “For the diagnosis of DM, HbA1c demonstrated an AUC of 0.86 (95% CI: 0.83-0.88).”

    Humansdetection of diabetes mellitusbloodn = 1,162

    Diagnostic accuracy of glycated hemoglobin and glycated albumin for detecting dysglycemia among community-dwelling older adults in China: a cross-sectional diagnostic study

    BMC geriatrics

  3. HbA1c predicts diabetes mellitus in silico.

    “SHAP analysis identified HbA1c level, blood glucose level, and age as the most influential predictors”

    In silico

    An Optimized and Explainable Machine Learning Framework for Diabetes Prediction Using Marine Predators Algorithm and SHAP

    Journal of personalized medicine

  4. HbA1c predicts diabetes mellitus in humans (for diabetes detection) (AUC 0.73 to 0.970).

    “Reported HbA1c sensitivity ranged from 45.5% to 89.4%, specificity from 80.0% to 100%, and area under the curve (AUC) from 0.73 to 0.970.”

    Reviewfor diabetes detection

    Comparative Diagnostic Performance of Short-Term Glycemic Markers and HbA1c for Diabetes and Prediabetes: A Systematic Review

    Journal of Scientific Research and Reports

More on Diabetes mellitus

Cognitive impairment

upin humans4OR 1.53

4 studies
  1. HbA1c is linked with a higher risk of cognitive impairment in humans (coefficient −0.16, 95% CI −0.23, −0.09).

    “Higher HbA1c was associated with shorter time to ADRD (coefficient −0.09; 95% CI −0.16, −0.02) and cognitive impairment (−0.16; 95% CI −0.23, −0.09)”

    Humansn = 4,571

    Apathy as a Potential Mediator of the Association Between Poor Glycemic Status and Incident Cognitive Impairment and Self-Reported Alzheimer’s Disease and Related Dementias in Older Adults: The Health and Retirement Study

    Journal of dementia and Alzheimer's disease

  2. HbA1c predicts cognitive impairment in humans (inpatients with diabetes mellitus; cognitive impairment assessed by MMSE and MoCA) (AUC 0.743 (MMSE) and 0.778 (MoCA)).

    “HbA1c had the best predictive ability for SGNT, with AUCs of 0.743 (MMSE) and 0.778 (MoCA).”

    Humansinpatients with diabetes mellitus; cognitive impairment assessed by MMSE and MoCAn = 87

    Study of cognitive impairment and diabetes control in older patients with diabetes

    Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế

  3. HbA1c is associated with cognitive impairment in humans (type 2 diabetes mellitus) (OR = 1.53, 95% CI: 1.01-2.30).

    “HbA1c (OR = 1.53, 95% CI: 1.01-2.30, P = 0.043)”

    Humanstype 2 diabetes mellitus

    Development and validation of a prediction model for cognitive impairment in elderly patients with type 2 diabetes

    Frontiers in neuroscience

  4. HbA1c predicts cognitive impairment in humans (type 2 diabetes).

    “Higher HbA1c levels, glucose variability, severe hypoglycemia, vascular complications, and inflammatory/metabolic markers significantly predicted higher cognitive impairment risk.”

    Reviewtype 2 diabetes

    Biobehavioral and Interpersonal Predictors of Cognitive Impairment in Older Adults With Type 2 Diabetes: A Systematic Review of Cohort Studies

    Biological research for nursing

More on Cognitive impairment

Age

upin humans2no changein humans1mixedin humans1OR 1.05

4 studies
  1. Age predicts HbA1c in humans (recurrent acute coronary syndrome) (OR 1.05, p = 0.040).

    “of HbA1c goal (OR 1.05, p = 0.040).”

    Humansrecurrent acute coronary syndrome

    ASSESSMENT OF SECONDARY PREVENTION GOALS ACHIEVEMENT AMONG PATIENTS WITH RECURRENT ACUTE CORONARY SYNDROME AT A TERTIARY CARDIAC CENTRE IN PAKISTAN

    Genetics and Molecular Research

  2. Age is associated with HbA1c in humans (type 1 or 2 diabetes) (r = 0.113, P = 0.097).

    “correlation between age and HbA1c was positive but not statistically significant (r = 0.113, P = 0.097)”

    Humanstype 1 or 2 diabetes

    Assessing cognitive impairment in Saudi Arabian diabetes patients: A cross-sectional study in Aseer region

    Journal of family medicine and primary care

  3. Age is associated with HbA1c in humans (Adjusted linear regression).

    “Adjusted linear regression showed a significant association between age and HbA1c (p < 0.001)”

    HumansAdjusted linear regressionn = 911

    Association between HbA1c chairside values and periodontitis

    Journal of dentistry

  4. Age is associated with HbA1c in humans (r = 0.284, p = 0.007).

    “A statistically significant but weak positive correlation was observed between age and HbA1c levels (r =0.284, p = 0.007).”

    Humansfemalesn = 129

    Reference interval for glycated hemoglobin (HbA1c) in non-pregnant, non-diabetic women in Ethiopia: a cross-sectional study

    The Pan African medical journal

Semaglutide

downin humans4

4 studies
  1. Semaglutide is associated with HbA1c in humans (type 2 diabetes) (7.75 ± 1.01% to 6.80 ± 0.88%; p < 0.00001).

    “HbA1c decreased from 7.75 ± 1.01% to 6.80 ± 0.88% after 12 months (p < 0.00001).”

    Humanstype 2 diabetesoral12 monthsn = 81

    Glycaemic and Cardiometabolic Effects of Oral Semaglutide in Patients Aged ≥65 Years with Type 2 Diabetes

    Endocrines

  2. Semaglutide is associated with HbA1c in humans (type 2 diabetes mellitus) (Median HbA1c from 8.9% to 7.8%; BMI from 34.8 to 32.6 kg/m2).

    “patients' median HbA1c was reduced from 8.9% [8.4 - 9.9] to 7.8% [7.2 - 8.4] (p < 0.0001)”

    Humanstype 2 diabetes mellitus12 monthsn = 186

    Real-world clinical and budget impact of semaglutide in type 2 diabetes mellitus in tertiary hospital in Saudi Arabia

    Frontiers in clinical diabetes and healthcare

  3. Semaglutide is associated with HbA1c in humans (Type 2 diabetes mellitus; initiated at hospital discharge after acute coronary syndrome) (64.3 ± 18.2 to 49.6 ± 10.4 mmol/mol).

    “HbA1c improved from 64.3 ± 18.2 to 49.6 ± 10.4 mmol/mol.”

    HumansType 2 diabetes mellitus; initiated at hospital discharge after acute coronary syndromeinjectable or orallowest dose108 ± 39 days73% malesn = 60

    Use of semaglutide after acute coronary syndrome: an exploratory retrospective study

    Journal of cardiovascular medicine (Hagerstown, Md.)

  4. Semaglutide is associated with HbA1c in humans (coexisting hypothyroidism and type 2 diabetes mellitus) (HbA1c −6.7%; BMI −4.04%; triglycerides −6.7%; HDL-C +9%).

    “At 6 months, mean HbA1c decreased by 6.7% (P < 0.001)”

    Humanscoexisting hypothyroidism and type 2 diabetes mellitusfinal dose = 14 mg daily6 monthsn = 51

    Modulation of metabolic syndrome components by oral semaglutide in hypothyroid-T2DM patients: a retrospective analysis

    Journal of medicine and life

More on Semaglutide

Dementia

upin humans3downin humans1+8% increased riskOR 1.6

3 studies
  1. HbA1c is linked with a lower risk of dementia in humans (HR 0.64; 95% CI, 0.51-0.79).

    “among those with Poor baseline control (≥9.0%), trajectory improvement conferred substantial neuroprotection, reducing the risk of dementia (HR 0.64; 95% CI, 0.51-0.79) and mortality”

    Humanstrajectory improvement in patients with Poor baseline control (≥9.0%) after SGLT2 inhibitor initiation

    HbA1c trajectories after SGLT2 inhibitor initiation and the risk of dementia

    Journal of Alzheimer's disease : JAD

  2. HbA1c is linked with a higher risk of dementia in humans (HR 1.39; 95% CI, 1.11-1.74).

    “in patients with Fair baseline control (7.0-8.9%), worsening to Poor control significantly increased dementia (HR 1.39; 95% CI, 1.11-1.74) and mortality risks.”

    Humansworsening to Poor control in patients with Fair baseline control (7.0-8.9%) after SGLT2 inhibitor initiation

    HbA1c trajectories after SGLT2 inhibitor initiation and the risk of dementia

    Journal of Alzheimer's disease : JAD

  3. HbA1c is associated with dementia in humans (older adults with diabetes without cognitive impairment or dementia at baseline) (OR 1.60, 95% CI 1.28–1.99).

    “elevated HbA1c levels in elderly diabetic patients were significantly associated with dementia (OR = 1.60, 95% CI: 1.28–1.99)”

    Reviewolder adults with diabetes without cognitive impairment or dementia at baselinen = 4,677

    Association of glycemic and metabolic biomarkers with cognitive impairment and dementia among elderly patients with diabetes: a systematic review and a dose-response meta-analysis

    BMC geriatrics

  4. HbA1c raises the risk of dementia in individuals with diabetes (8% increased risk).

    “an 8% increased risk of dementia was associated with every 1% increase in HbA1c”

    Reviewin individuals with diabetesevery 1% increase in HbA1c

    Impact of Microvascular Complication Burden on the Risk of Dementia and Cognitive Decline in Patients With Diabetes: A Systematic Review of Latest Evidence

    Cureus

More on Dementia

SGLT2 inhibitors

downin humans3−38% diabetic patients achieved better control

3 studies
  1. SGLT2 inhibitors are associated with HbA1c in patients with T2DM.

    “Regarding inflammatory markers, ferritin levels declined significantly (p = 0.001), along with HbA1c values (p < 0.001), ESR (p = 0.02), and CRP concentrations (p = 0.007).”

    Human trialin patients with T2DM6 monthsn = 51

    Cardiovascular, Renal, and Metabolic Effects of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Prospective Cohort Study

    Research SquarePreprint

  2. SGLT2 inhibitors are associated with HbA1c in humans (type 2 diabetes; uncontrolled comparison with baseline) (Decreased by 1.0% (95% CI 0.8–1.1)).

    “HbA1c decreased by 1.0% (95% CI 0.8-1.1; n = 398)”

    Humanstype 2 diabetes; uncontrolled comparison with baseline12 monthsn = 398

    Real-World Renal and Metabolic Outcomes of SGLT-2 Inhibitor Therapy in Patients with Type 2 Diabetes Mellitus

    Journal of clinical medicine

  3. SGLT2 inhibitors are associated with HbA1c in humans (type 2 diabetes mellitus; uncontrolled baseline-to-follow-up comparison).

    “After six months, significant reductions were observed in body mass index, systolic blood pressure, heart rate, HbA1c,”

    Humanstype 2 diabetes mellitus; uncontrolled baseline-to-follow-up comparisonempagliflozin 10 mg/day or dapagliflozin 10 mg/day6 monthsn = 51

    Cardiovascular, Renal, and Metabolic Effects of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Prospective Cohort Study

    Research SquarePreprint

  4. SGLT2 inhibitors are associated with HbA1c in diabetic patients (38.2% of diabetic patients achieved better control).

    “38.2% of diabetic patients achieved better HbA1c control”

    Humansin diabetic patients

    Safety & efficacy of sodium glucose co-transport 2 (SGLT2) inhibitors in elderly patients with heart failure

    Frontiers in cardiovascular medicine

More on SGLT2 inhibitors

Frailty

upin humans3OR 2.4

3 studies
  1. Frailty is associated with HbA1c in humans (type 2 diabetes mellitus) (8.003±2.395 vs 6.774±1.741, p=0.036).

    “The HBA1c level of patients with frailty was significantly higher compared to those without frailty (8.003±2.395 vs 6.774±1.741; p=0.036)”

    Humanstype 2 diabetes mellitusn = 113

    Prevalence and Associated Factors of Frailty among Geriatric Patients with Type 2 Diabetes Mellitus at Victoriano Luna Medical Center: A Cross-sectional Study

    Philippine Journal of Internal Medicine

  2. Frailty is associated with HbA1c in humans (type 1 diabetes) (p = 0.025).

    “Frailty was associated with higher HbA1c (p = 0.025) and lower MoCA scores (p = < 0.001).”

    Humanstype 1 diabetesn = 83

    The impact of frailty on glycaemic control in older adults with type 1 diabetes: An observational study

    Diabetic medicine : a journal of the British Diabetic Association

  3. HbA1c is associated with frailty in humans (HbA1c ≥ 9.0% in older adults with type 2 diabetes) (OR = 2.4, 95%CI 1.08–5.3).

    “having HbA1c ≥ 9.0% (OR = 2.4, 95%CI 1.08–5.3)”

    HumansHbA1c ≥ 9.0% in older adults with type 2 diabetesn = 840

    Cognitive frailty and associated factors in older adults with type 2 diabetes in rural Vietnam

    BMC geriatrics

Cardiovascular disease

upin humans3HR 1.21

3 studies
  1. HbA1c is associated with cardiovascular disease in humans (unadjusted analyses).

    “Higher HbA1c levels were associated with increased odds of cardiovascular outcomes in unadjusted analyses.”

    Humansunadjusted analysesn = 30,804

    Association of HbA1c With Cardiovascular Outcomes: The Role of Diabetes Duration and Cardiometabolic Factors

    Cureus

  2. HbA1c is linked with a higher risk of cardiovascular disease in humans.

    “HbA1c similarly enhanced risk of CVD.”

    Humans

    Cardiovascular Disease Risk Prediction in Type 1 Diabetes over 30 Years

    ADA Scientific Sessions 2026 abstract

  3. HbA1c is linked with a higher risk of cardiovascular disease in humans (type 1 diabetes) (HR 1.21, p<0.05).

    “most important CVD factors for males were age, stroke/congestive heart failure history, mean (M) pulse, M insulin dose, TRG, and M HbA1c [hazard ratio (HR):1.09 p<0.0001; 3.84 p<0.01; 1.04 p<0.05; 3.27 p<0.05; 2.55 p<0.05; 1.21 p<0.05]”

    Humanstype 1 diabetes~30 yearsmalesn = 761

    Relative Importance of CVD Risk Factors in Type 1 Diabetes Males and Females

    ADA Scientific Sessions 2026 abstract

More on Cardiovascular disease

Liraglutide discontinuation

upin humans1

1 study
  1. liraglutide discontinuation is associated with HbA1c in humans (median +2.2% (range 0.8–3.5%)).

    “After 12 weeks of liraglutide discontinuation, all patients experienced increases in HbA1c and body weight, with median changes of 2.2% (24 mmol/mol; range 0.8–3.5% [9–38 mmol/mol]; p=0.026) and 3.7% (range 3.2–4.8%; p=0.001), respectively.”

    Human trial12 weeksn = 5

    Liraglutide use in congenital generalized lipodystrophy: glycemic and metabolic outcomes

    Frontiers in endocrinology

  2. liraglutide discontinuation is associated with HbA1c in humans (congenital generalized lipodystrophy; after liraglutide discontinuation) (Median increase, 2.2%).

    “Twelve weeks after liraglutide discontinuation, median HbA1c and body weight increased by 2.2% (p=0.026) and 3.7% (p=0.001), respectively.”

    Human trialcongenital generalized lipodystrophy; after liraglutide discontinuation12 weeks after discontinuation

    Liraglutide use in congenital generalized lipodystrophy: glycemic and metabolic outcomes

    Frontiers in endocrinology

Hydroxytyrosol-glucuronide

downin humans1

1 study
  1. Hydroxytyrosol-glucuronide is associated with HbA1c in humans during the EVOO period (Spearman’s rho = −0.49).

    “During the EVOO period, increases in urinary hydroxytyrosol-glucuronide were inversely correlated with decreases in HbA1c (Spearman’s rho = −0.49, p = 0.011) and with reductions in WHR (rho = −0.38, p = 0.048), whereas no significant associations were observed for waist circumference (rho = −0.20, p = 0.300) or WHtR (rho = −0.20, p = 0.310”

    Human trialduring the EVOO period4 weeksn = 30

    Corbella Extra Virgin Olive Oil, Urinary Phenolic Metabolites, and Exploratory Cardiometabolic Outcomes in Healthy Young Adults: The HEVOOC Trial

    Antioxidants (Basel, Switzerland)

  2. Hydroxytyrosol-glucuronide is associated with HbA1c in humans during EVOO intake (rho = -0.49, p = 0.011).

    “urinary hydroxytyrosol-glucuronide during EVOO intake were inversely correlated with changes in HbA1c (Spearman's rho = -0.49, p = 0.011)”

    Human trialduring EVOO intaken = 28

    Corbella Extra Virgin Olive Oil, Urinary Phenolic Metabolites, and Exploratory Cardiometabolic Outcomes in Healthy Young Adults: The HEVOOC Trial

    Antioxidants (Basel, Switzerland)

More on Hydroxytyrosol-glucuronide

Catecholamines

downin humans1

1 study
  1. Catecholamines are associated with HbA1c in humans (changes following AM aerobic exercise training in adults with overweight or obesity) (r = −0.61, p = 0.01).

    “This change in catecholamines was correlated with changes in HbA1C (r = −0.61, p = 0.01)”

    Human trialchanges following AM aerobic exercise training in adults with overweight or obesity15 weeks

    Time of Day of Aerobic Exercise Training Alters the Metabolome in Adults with Overweight or Obesity: A Secondary Analysis

    Metabolites

More on Catecholamines

Disposition index

upin humans1

1 study
  1. HbA1c is associated with disposition index in humans (Greater HbA1c reduction in multivariable models).

    “In multivariable models, greater HbA1c reduction was associated with higher DI at Week 104.”

    Human trialGreater HbA1c reduction in multivariable models104 weeks

    β‐Cell Recovery Patterns With Initial Combination Versus Stepwise Therapy in Newly Diagnosed Type 2 Diabetes: <scp>TRIPLE</scp> ‐ <scp>AXEL</scp> Post Hoc Analysis

    Diabetes, obesity & metabolism

More on Disposition index

Nutrition counseling and exercise program

downin humans1

1 study
  1. Nutrition counseling and exercise program is associated with HbA1c in humans (breast cancer survivors with BMI ≥ 25 kg/m2; single-arm study).

    “At 3 months, significant reductions were observed in BMI, body fat composition, and hemoglobin A1c (HbA1c)”

    Human trialbreast cancer survivors with BMI ≥ 25 kg/m2; single-arm study3 monthsn = 59

    Quality-of-Life and Weight Loss Outcomes Following an Individualized Nutrition and Physical Activity Counseling Program in Breast Cancer Survivors: A Prospective Single-Arm Pilot Study

    Cancers

More on Nutrition counseling and exercise program

All 228

Funding

6 grants since 2018

National Institute of Diabetes and Digestive and Kidney Diseases$3.4MUK Research and Innovation£734KWellcome Trust£4.9M

Contains public sector information licensed under the Open Government Licence v3.0.

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    HbA1c has a U-shaped association with mortality in a general-population cohort, while a preprint links higher HbA1c with greater frailty and mortality in adults with diabetes. Human trials report reductions with semaglutide, tirzepatide and resistance training; a dapagliflozin trial shows no clear effect on HbA1c.

  2. Summary rewritten as its findings changed.

    As it read before

    Higher HbA1c is associated with greater frailty in adults with diabetes in a preprint, while a general-population cohort reports a U-shaped association with mortality. A study in type 2 diabetes links HbA1c to cardiovascular disease or death and kidney-function decline; trials report reductions with semaglutide, tirzepatide and resistance training, while a dapagliflozin trial reports no between-group HbA1c difference.

  3. Summary rewritten as its findings changed.

    As it read before

    Higher HbA1c is associated with frailty in adults with diabetes in a preprint, while a general-population cohort reports a U-shaped association with mortality. Another human study links HbA1c to multimorbidity; trials in type 2 diabetes report reductions with metformin, semaglutide and tirzepatide.

  4. Summary rewritten as its findings changed.

    As it read before

    Human studies associate HbA1c with mortality and multimorbidity. Mortality associations are U-shaped in the general population; a preprint links higher HbA1c to greater frailty in adults with diabetes. Human trials report reductions with semaglutide, tirzepatide and metformin in type 2 diabetes.

  5. Summary rewritten as its findings changed.

    As it read before

    Human trials report HbA1c reductions with semaglutide in type 2 diabetes and with exercise in prediabetes. Human studies link higher HbA1c to frailty, disability, mortality and diabetic complications. Cardiac biomarker results differ: a cross-sectional preprint reports an association with hsTnT, while a study in people with prediabetes finds none.

Latest

See all 4,472 papers on HbA1c